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1 INTRODUCTION  
1.1 Drug-induced neuropathy  
Peripheral neuropathy is a side effect of many drugs used in the treatment of a variety of 
disorders, including cancer, infections, epilepsy, connective tissue disorders and cardiac 
arrhythmias. The severity of this complication may range from some loss of sensory function 
and mild paraesthesias to neuropathic pain, severe ataxia and weakness leading to 
pronounced disability. The involvement of autonomic nerve fibers with orthostatic 
hypotension, impotence and incontinence may further reduce the quality of life (Hilkens & 
van den Bent, 1997). 
Especially cancer patients, undergoing chemotherapy with platinum-derivatives, taxoides or 
vinca-alcaloides are often left with permanent evidence of peripheral nerve damage 
(Schattschneider et al, 2001; Screnci & McKeage, 1999). With regard to this neurotoxic 
effect, total dose is restricted, which may result in therapeutic failure. 
Although most of anti-cancer drug induced neuropathies have been extensively described 
clinically over the past 20 years, little is known about the pathophysiological mechanisms. 
Elucidating of these mechanisms might enable oncologists in the future to counteract 
neuronal damage with new chemoprotective strategies. 
 
1.2 Use and obstacles of platinum based chemotherapy 
1.2.1. Indication 
The platinum complex cisplatin (cis-diamminedichloroplatinum [II]), first described as an 
antineoplastic agent in 1965 by Rosenberg et al., is among the most frequently used 
chemotherapeutics, indicated against a broad range of solid tumors, which primarily were 
testicular, ovarian and bladder neoplasms (Cersosimo, 1989; Higby et al., 1974). Recently 
the spectrum of indications has been expanded including now endometrium-, cervix-, 
prostate-carcinomas; osteosarcomas as well as head and neck tumors (Petsko, 1995). 
Additionally, this substance has shown its efficacy against small cell and non-small cell lung 
cancer (Eberhardt et al., 1998; Havemann & Wolf, 1997) and is being used in the therapy of 
gastrocarcinomas as well (Kath et al., 2000; Konishi et al., 1998). 
Cisplatin is administered intravenously in 3-5 courses spread over several weeks to months. 
Individual courses are usually 20-40 mg/m2 (Windebank, 1996). 
 
1.2.2 Unwanted side effects 
The use of platinum compounds is associated with several systemic adverse events. Short 
term phenomena like nausea and vomiting are seen in nearly all patients treated with 
cisplatin (Hamers et al, 1991). 
More threatening are the effects of platinum complexes, which appear at higher cumulative 
doses. In former times, the dose escalation of cisplatin therapy was limited in first instance by 
renal toxicity manifested as a marked reduction of glomerular as well as tubular function in 
15-30% of patients (Cornelison & Reed, 1993). 
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Such functional impairment causes protein- and glucosuria, hyperuricaemia and 
hypercreatininaemia, serum electrolyte disturbances and is a serious risk factor of an acute 
kidney failure (Lau, 1999). Both renal and gastrointestinal side effects, however, have been 
reduced considerably in the clinic by several measures such as careful saline hydration 
(Alberts & Noel, 1995) as well as the use of antiemetics (Hamers et al, 1991; Screnci & 
McKeage, 1999). Thus, cisplatin-induced neurotoxicity represents now the predominant 
complication during cisplatin chemotherapy. 
 
 
1.3 Neurotoxicity – the major dose limiting factor of cisplatin 
chemotherapy 
About 20% of the patients are unable to complete a full course of cisplatin chemotherapy due 
to neurological damage (Cano et al., 1998; McDonald & Windebank, 2002). The spectrum of 
cisplatin-induced neurotoxicity includes peripheral sensory neuropathy (Alberts and Noel, 
1995; Boogerd, 1995; Cersosimo, 1989; LoMonaco et al., 1992; Hamers et al., 1991; Hilkens 
& van den Bent, 1997; Meijer et al., 1999), ototoxicity (Alberts and Noel, 1995; Smoorenburg 
et al., 1999), and, rarely, autonomic neuropathy with orthostatic hypotension and gastric 
paresis, Lhermittes symptom (Cersosimo,1989), optic neuropathy (Cersosimo, 1989; Hilkens 
& van den Bent, 1997), focal encephalopathy, cortical blindness and seizures (Alberts and 
Noel, 1995; Cersosimo, 1989; Hilkens & van den Bent, 1997). 
Of these, peripheral sensory polyneuropathy (PNP) is by far the most common dose limiting 
toxicity (Hadley et al., 1979; Ozols & Young, 1984; Roelofs et al., 1984; Thompson et al., 
1984). 
 
 
1.3.1 Clinical signs 
PNP was first reported as a side effect following cisplatin administration by Kedar et al. in 
1978. The actual literature data about the incidence of cisplatin-associated neuropathy are 
varying from 30 to 100% of treated patients, most likely due to the differences in patient 
populations, therapy protocols and evaluation methods used. The overall incidence of any 
grade of neuropathy according to a large prospective Dutch study was 47%, and the 
incidence in long survivors was even higher – 61% (Hilkens & van den Bent, 1997; van der 
Hoop et al., 1990). 
The main prognostic factor for the severity of neuropathy is the cumulative dose of cisplatin. 
According to recent clinical data cisplatin-induced neuropathy is a strongly dose depended 
predominantly large fiber sensory PNP which develops after cumulative doses of 300 mg/m2 
or higher (Cersosimo, 1989; Ongerboer de Visser et al., 1985; van der Hoop et al, 1990). 
The single-dose intensity also seems relevant to the development of neuropathy (Cavaletti et 
al., 1992a). 
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Initial symptoms are usually numbness and paraesthesias in the stocking-and-glove 
distribution extending proximally with increasing cumulative dose, loss of tendon reflexes and 
a decrease in mainly thick fiber mediated sensory qualities such as vibration perception, fine 
touch perception and proprioception. This can lead to difficulties in small motor coordination. 
Neuropathy becomes markedly disabling at a cumulative dose of about 600 mg/m2. The 
sense of joint position becomes impaired, resulting in profound sensory ataxia, including gait 
disturbances, loss of manual dexterity and becoming wheel-chair bound (Alberts & Noel, 
1995). Motor power remains intact (Boogerd, 1995; Hilkens & van den Bent, 1997; 
Schattschneider et al., 2001). Decreased pain and temperature sensation are not prominent 
in clinical presentation. Pain is not a symptom of cisplatin-induced PNP (Krarup-Hansen et 
al., 1993; Roelofs et al., 1984). Some patients develop Lhermitte’s sign or experience 
paraesthesias and electric shock sensation on stretching the arms or legs. This corresponds 
with electrophysiological and pathological findings of dorsal column involvement (Walsh et 
al., 1982).  
The unambiguous information concerning the prognosis and possible predispositional factors 
of PNP has not been reported. The progrediental course can often be observed. Neuropathy 
worsens with further treatment and symptoms may begin or progress up to four months after 
cisplatin treatment has been discontinued (Alberts & Noel, 1995; Schattschneider, 2001). 
Recovery is usually incomplete and 30 to 50% of cases are irreversible even years after 
cessation of chemotherapy (Alberts & Noel, 1995; Strumberg et al., 2002). 
Ototoxicity occurs almost as frequently as neuropathy and is considered to be due to the 
widespread loss of outer hair cells in the organ of Corti (Alberts & Noel, 1995). It is 
characterized by progressive hearing loss in the high frequency range over 4000 Hz 
(Smoorenburg et al., 1999). The clinical spectrum varies between otalgia, tinnitus, vestibular 
alterations and severe deafness (Schaefer et al., 1985). Although tinnitus is reversible, 
cisplatin-induced hearing loss is progressive and irreversible (Schweitzer, 1993).  
The involvement of autonomic nerve fibers presenting mostly as a dysfunction of heart and 
orthostatic regulation has been occasionally reported (Rosenfeld & Broder, 1984). 
Clinical signs of central nervous system involvement have also been reported (Highley et al., 
1992; LoMonaco et al, 1992; Philip et al., 1991), including focal encephalopathy, epileptic 
seizures and cortical blindness. Ocular toxicity, including optic nerve degeneration and retinal 
infarcts, is a common complication of intracarotid cisplatin administration (Maiese et al., 
1992). 
 
1.3.2 Electrophysiological findings 
Cisplatin-induced nerve conduction changes indicate the damage of large myelinated 
sensory fibers in both animal models and human studies. Typically, nerve conduction studies 
show absence or reduction up to 80-90% of the amplitude of the sensory action potentials, 
with only a mild to moderate decrease of sensory nerve conduction velocities (SNCV), and 
prolonged or absent H-reflexes, suggesting an axonal type of PNP (Daugaard et al., 1987; 
Krarup-Hansen et al., 1993; LoMonaco et al., 1992; Roefols et al., 1984; Thompson et al., 
1984; Verdu et al., 1999). 
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Motor nerve conduction and electromyography (EMG) are usually normal or only mildly 
affected, indicating that the disturbance primarily involves sensory nerves (Alberts & Noel, 
1995; Boogerd, 1995; Cerosimo, 1989; Hilkens & van den Bent, 1997). Somatosensory 
evoked potential studies showed slowing of conduction velocity along peripheral and central 
pathways after tibial nerve stimulation compatible with a toxic effect on the dorsal root 
ganglia cells causing “dying back” axonal degeneration of central and peripheral nerve fibers 
(Hansen et al., 1989; Krarup-Hansen et al., 1993). 
 
1.3.3 Morphopathological findings 
Using classical histological and morphological techniques it has been shown that the clinical 
features of cisplatin-induced polyneuropathy result from predominant loss of large myelinated 
sensory fibers. Pathological examinations of sural nerve generally reveal axonal 
degeneration with a mild secondary segmental demyelination of large myelinated sensory 
fibers (Thompson et al., 1984; Walsh et al., 1982). Morphometric analysis has confirmed a 
disproportionate loss of large myelinated fibers (Gastaut & Pellissier, 1985). Experimental 
and autopsy studies further suggested sensory neurons and satellite cells to be the main 
targets of cisplatin neurotoxic effects (Cavaletti et al., 1992b; Riggs et al., 1988; Tomiwa et 
al.,1986). In rodents exposed to cisplatin early morphological alterations in DRG neurons 
were characterized by shrinkage of the cytoplasm, cell nucleus and particularly by reduction 
in the nucleolar size (Barajon et al., 1996; McKeage et al., 2001; Muller et al., 1990). 
Interestingly, comparative morphological analysis of DRG neurons and satellite cells in 
cisplatin treated rats showed rather satellite cells to have severe ultrastructural changes in 
the nucleus and cytoplasm, which were more prominent than in the corresponding neurons, 
suggesting that the satellite cells are also involved in the pathophysiology of cisplatin-
induced PNP (Corsetti et al., 2000). 
 
1.4 Antineoplastic activity and unwanted side effects as a 
consequence of Pt-DNA adduct formation 
 
1.4.1 Interaction of Pt 2+ - complexes with proteins and nuclear DNA 
In the intracellular environment cisplatin is changed into Pt 2+ hydroxo –complexes, which 
have a strong affinity to nucleophilic epitopes of proteins and nucleic acids. Pt-DNA 
modifications are assumed to represent by far the most important mediators of both the 
antineoplastic activity and the undesired toxic side effects of this potent anticancer drug. A 
very fast formation of intermediate (“early”) monovalent Pt-DNA-adducts is followed by their 
conversion into “late” bivalent intra- and interstrand crosslinks within few hours (Bernges & 
Holler, 1991; Knox et al., 1986). Three different structures, linked at the N-7 position of 
adenines and guanines, have been identified as the major reaction products with DNA (figure 
1): the intrastrand adducts cis-Pt(NH3)2d(pGpG), cis-Pt(NH3)2d(pApG) and cis-
Pt(NH3)2d(pGpXpG), representing more than 95 % of DNA damage, and the interstrand 
crosslink cis-Pt(NH3)2d(GMP)2  (Fichtinger-Schepman et al., 1985; Huang et al., 1995). 
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Figure 1 Cisplatin-induced Pt-DNA adducts 
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1.4.2 Pharmacokinetic factors strongly influence adduct formation 
The formation of adducts is influenced by several pharmacokinetic factors. Their regulation is 
genetically determined (figure 2).  
Kidney function, organ perfusion (Schellens et al., 1996) and protective mechanisms like the 
blood-brain barrier control the extent of cellular drug exposure.  
The intracellular platinum content of an individual cell depends on the balance between the 
drug import and export through the cellular membrane. While the existence of an active 
membrane import mechanism for cisplatin is still under discussion, there is at least one 
membrane protein known to perform an ATP-dependent transport of platinum complexes out 
of the cytoplasm into the extracellular space: MRP 2 (multidrug resistance protein) or cMOAT 
(canalicular multispecific organic anion transporter) – a membrane protein of the ABC (ATP 
binding cassette) transporter group. An augmented expression of MRP 2 can significantly 
increase the cellular platinum export rate and thus prevent the drug from reaching its 
molecular targets (Borst et al., 1999; Demeule et al., 1999; Klein et al., 1999; Matsunaga et 
al., 1998).  
Cytoplasmatic detoxification by concurrent binding to glutathione or metallothionein is 
another pharmacokinetic factor which may influence the final nuclear DNA platination level. 
(Chao, 1996; Ishikawa & Ali-Osman, 1993; Meijer et al., 1992 & 2000; Pattanaik et al., 1992). 
 
1.4.3 Pt-DNA adducts are substrates for the DNA repair machinery 
Cells are equipped with several protective mechanisms of DNA repair which are required for 
maintaining the integrity of the genome exposed to environmental or endogenous DNA 
damaging agents. Cisplatin-induced DNA adducts are known to be eliminated through a 
pathway, called nucleotide excision repair (NER) (Crul et al., 1997; de Laat et al., 1999; 
Sancar, 1996; van Steeg et al., 2000). A set of several proteins is responsible for adduct 
recognition, unwinding of DNA, incision, excision of adduct bearing DNA fragments and at 
last for DNA synthesis and ligation (Figure 2). The lack of at least one functional NER 
component, like the damage recognizing XPA protein, can result in an extreme sensitivity of 
cells to the acute toxicity of cisplatin (Asahina et al., 1994; Dabholkar. et al 1994; Dijt et al., 
1988; States & Reed 1996). By measuring the in vivo Pt-DNA adduct repair kinetics in 
various cell types, Liedert has demonstrated in an experimental model of XPA-deficient mice, 
that such hypersensitivity was due to an increased formation and / or reduced repair of 
specific Pt-DNA adducts like Pt-(GG) intrastrand crosslinks (Liedert, 2001).  
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1.4.4 The tolerance to Pt-DNA adducts determines the cellular sensitivity to 
platinum based chemotherapy 
The degree of tolerance to persisting (unrepaired) Pt-DNA lesions determines the fate of 
each cell, which may be survival or apoptosis (Figure 2; Crul et al., 1997; Fajac et al., 1996; 
Ormrod et al., 1994 & 1996; Sorenson et al., 1990). Pt-DNA adducts hinder replication and 
transcription and recruit proteins like mismatch repair proteins (Branch et al., 2000; Lage & 
Dietel, 1999; Samimi et al., 2000) which directly induce cell death, activating p53 or p73 
dependent pathways (Hawn et al., 1995; Li, 1999). The relative contribution of different 
mechanisms to the antineoplastic activity on the one hand and to the unwanted side effects 
on the other is far from being understood. Furthermore, the relative toxicity of the structurally 
different DNA adducts is also discussed controversially. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Antineoplastic activity and unwanted side effects of cisplatin 
depend on formation, repair and tolerance to Pt-DNA adducts
drug import / export by membrane transporters
cytoplasmatic detoxification
kidney function & organ perfusion 
programmed cell death
nucleotide excision
repair proteins
complete
repair
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incision
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adduct  formation
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1.4.5 Formation, repair and tolerance to Pt-DNA adducts are cell-type specific 
and interindividually variable 
Pt-DNA-adduct accumulation and elimination rates as well as the degree of tolerance to such 
DNA damage are known to be cell type specific (Fichtinger-Schepman et al., 1989; Johnsson 
et al., 1995; Mustonen et al., 1989; Terheggen et al., 1987). This may partly explain the 
restriction of unwanted side effects to some tissues. Due to the differences in the genetic 
background, prominent interindividual heterogeneities in adduct levels can also be observed 
(Meijer et al., 1999), leading to a broad range of both the therapeutic efficiency and toxicity to 
normal cells. 
 
1.4.6 Pathophysiological models for platinum induced neurotoxicity 
The contribution of different cisplatin-induced toxic effects to neuronal damage is unclear. 
Microtubuli cross-linking caused by platinum protein interaction might lead to the impairment 
of fast axonal transport (Boekelheide et al., 1992; Gao et al., 1995; Russell et al., 1995). 
Both autopsy and animal studies have demonstrated that cisplatin-induced neurotoxicity is 
associated with platinum accumulation in the DRG whereas the levels of DNA platination in 
the brain and spinal cord proved to be significantly lower (Gregg et al., 1992; Poirier et al., 
1992 & 1993; Terheggen et al., 1989; Thompson et al., 1984). As DRG cells are located 
outside the central nervous system (CNS), they are not protected by the blood-brain barrier 
(BBB), which obviously represents an effective defense mechanism against cisplatin 
exposure. Central neurotoxicity can be observed in the situations where the BBB is 
weakened, e.g. in the cases of brain tumors or by high dose mannitol co administration 
(Fountzilas et al., 1991). 
The primary damage of DRG cells explains the sensory type of cisplatin-induced PNP with 
the preservation of motor nerve fibers.  
Hence, the molecular mechanisms of neurotoxicity might be related to DNA damage in the 
DRG sensory neurons and satellite cells by formation of Pt-DNA adducts. 
Some studies point out, that neurotoxicity is mainly due to the cisplatin-induced apoptosis of 
DRG neurons (Gill & Windebank, 1998; Fischer et al., 2001; McDonald & Windebank, 2002). 
Other investigations focus on DRG satellite and Schwann cells, which have been shown to 
develop severe ultrastructural changes after cisplatin exposure (Corsetti et al., 2000; 
Sugimoto et al., 2001; Terheggen et al., 1989). As far as the satellite cells are involved in 
several essential neuronal functions such as intra- and extraneuronal transport and the 
trophic function, it seems quite plausible that at least partially the loss of DRG neurons can 
be secondary to cisplatin-induced glial damage. 
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1.5 Analytic amenability of Pt-DNA adducts 
In order to improve the knowledge about the molecular mechanisms of platinum related 
cytotoxicity, numerous analytical attempts have been made within the past 20 years to detect 
and quantify Pt-DNA adducts in experimental systems and in clinical specimens. Among 
these methods are spectroscopic procedures like nuclear magnetic resonance (NMR) 
(Fichtinger-Schepman et al. 1982), atom absorption spectrometry (AAS) (Reed et al., 1990a, 
b; & 1993) or inductively coupled plasma mass spectroscopy (ICP-MS) (Bonetti et al., 1996), 
32P-postlabeling techniques (Blommaert & Saris 1995; Farah et al. 2000; Pluim et al. 1999; 
Welters et al. 1997 & 1999a, b), immuno-analytical assays based on polyclonal or 
monoclonal antibodies (Chao et al. 1994; Blommaert et al. 1996; Fichtinger-Schepman et al. 
1985 & 1987; Meijer et al., 1997 & 1999; Poirier et al. 1982; Sundquist et al. 1987; 
Terheggen et al. 1987 & 1991) or PCR-based techniques (Grimaldi et al., 1994; Bingham et 
al., 1996;). Further progress in understanding clinical resistance and unwanted side effects 
was hampered, because some of these methods proved to be either not sensitive enough for 
the measurement at the relevant DNA platination levels (NMR, PCR), or to be unable to 
distinguish between specific lesions (AAS, ICP-MS, ELISA, immunohistochemistry), or could 
not work at the level of single cells (all methods except immunohistochemistry). 
The recent development of an “Immuno-Cytological Assay” (ICA), based on anti-(Pt-DNA 
adduct) MABs allows one to quantitate the defined Pt-DNA adducts at a single cell level and 
to realize molecular dosimetry of these lesions (Liedert 2001). 
 
1.6 Aim of the study and future perspectives 
It is unclear, whether the enhanced adduct formation, insufficient DNA repair or poor adduct 
tolerance is responsible for the sensitivity of nervous tissue to platinum based chemotherapy. 
It also remains to clarify whether glial cells or rather neurons are prone to functional damage 
by cisplatin.  
This report demonstrates, that adduct-specific single cell dosimetry of Pt-DNA adducts by 
means of the immunocytological assay is suitable to elucidate these questions. 
Investigations using XPA- and XPC-knockout mice give a detailed insight into the 
mechanism of the NER adduct recognition step and its importance concerning neurotoxicity. 
In the future, single cell quantification of Pt-DNA adducts might be a powerful tool for the 
development and testing of chemoprotective substances, which should meet contradictory 
demands: effectively prevent patients from the therapy induced neuronal damage without 
influencing the antineoplastic activity of cisplatin (Awada & Piccart, 2000; Babu et al., 1999; 
Hanada et al., 1999; Hartmann et al., 1999; Korst et al., 1998, Links & Lewis, 1999; Osman 
et al., 2000). 
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2  RESULTS & COMMENTS 
 
2.1 Optimization of the immuno-cytological assay (ICA) for the 
measurement of Pt-DNA adducts in nervous tissues 
The method of “Immuno-Cytological Assay” (ICA), firstly established in the Institute of Cell 
Biology, University of Essen, by Seiler et al. (1993) and Thomale et al. (1994), has been 
recently developed by Liedert (2001) to a highly sensitive and specific monoclonal antibody-
based Pt-DNA-adduct quantification technique, which basically allows the measurement of 
these DNA lesions at the single cell level both within cultured cells and in biopsy material. 
To enable the cell type-specific molecular dosimetry of cisplatin-induced DNA lesions within 
the structures of the central and peripheral nervous system in the in vivo mouse model, this 
method has been technically optimized and supplied with the immunohistochemical cell type 
identification step. 
 
2.1.1 Preparation of nervous tissue samples for ICA procedure 
Traditional ways of tissue sample preparation for immunohistochemical procedures, like 
glutaraldehyde – paraformaldehyde fixation with paraffin embedding or perfusion of organs 
with fixative solutions in situ, significantly decrease permeability of cellular and nuclear 
membranes for the antibodies designed against intranuclear antigens. Therefore, to obtain 
the optimal penetration of anti-(Pt-DNA) MABs into the cell nuclei, the use of microtome 
sections from native frozen tissue specimens is required. This method generally ensures 
good preservation of cell structure and antigens (Harlow & Lane, 1988). However, the 
principal disadvantage of preparing the samples from non-fixed nervous tissues is that the 
nervous cells are extremely sensitive to acute postmortal anoxia and therefore are prone to 
early development of postmortal structural changes with the loss of target antigens. Thus, 
several peculiarities have been invented to adjust the preparation technique for gentle 
tissues of DRG and the spinal cord and to shorten the time window from the death point until 
the deep freezing of samples. 
To prevent the nervous structures from early enzyme-induced postmortal morphological 
damage, the carcass was kept in ice during the organ dissection and the exposed organs 
were constantly rinsed with PBS (0.01M, pH 7.4) precooled to 4°C.  
A midline dorsal longitudinal incision over the spine and an expanded microlaminectomy 
served as quick and non-traumatic way to expose the lumbar DRGs and the lumbar part of 
the spinal cord (figure 3). 
Freshly dissected tissue samples were immediately submerged into “Tissue-Tek O.C.T. 
Compound” embedding medium and deep frozen in liquid nitrogen. Frozen tissue blocks 
were placed into precooled freezing vials and stored at -80°C. 
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Figure 3 Preparation of nervous tissue samples for the ICA procedure 
A. Lumbar part of the spinal cord (SC) with lumbar DRG at 
both sides is gently exposed by microlaminectomy; both 
sciatic nerves (SN) are exposed between muscles and 
pelvic bones. The exposed nervous tissues are constantly 
rinsed with precooled (4°C) PBS 
 
B. Lumbar DRG (arrow head) with radices at both sides are 
exposed and dissected microscopically 
A B 
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2.1.2 Immuno-histochemical identification of different neuronal cell types 
The cell sensitivity to cisplatin as well as the Pt-DNA-adduct accumulation rates are known to 
be tissue and cell type specific (1.4.5). However, it was to clarify, whether there are any 
differences in adduct accumulation and repair rates between the neuronal and glial cells as 
well as between the central and peripheral nervous system cells and whether this might 
correlate with the type of cisplatin-induced neurological deficit. Therefore, it proved to be 
essential to quantify the Pt-DNA-adduct levels separately for neuronal and glial cells of the 
DRG or spinal cord as well as for the Schwann cells of the sciatic nerve. A double-labeling 
experiment, where cell type specific antigens and the Pt-DNA-adducts are marked with two 
different detection reagents in the same specimen, should obviously be the method of choice 
to achieve this goal. The obstacle one has to overcome is that the strong proteolytic 
cleavage of cytoplasmic and nuclear proteins, which could serve as type specific antigens, is 
required for optimal immunostaining of Pt-DNA-adducts. The solution of this problem is 
performing the cell type identification and the adduct immunostaining within the same tissue 
section sequentially as two independent steps of one assay, where at the first step the cell 
types are identified immuno-histochemically and this information is stored as a digital image, 
which is then used to identify cell types retrospectively after the Pt-DNA-adducts have been 
labeled in the second step.  
The “NeuroTraceä 530/615 red fluorescent Nissl Stain” was used to identify the neurons 
within the tissue sections of DRG or spinal cord. Glial cells of the spinal cord, DRG or sciatic 
nerve were stained with anti-CNPase MABs, secondary labeled with fluorochrome (“ALEXA 
FLUOR 488”). The nuclear DNA was counterstained with DAPI. The cell type identification 
was performed as analysis of digital images taken from the slides by means of a laser scan 
microscope. The neurons were determined by red, glial cells by green fluorescence, the cell 
nuclei – by DAPI (blue) fluorescence (figure 4). The images were stored electronically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Immunohistochemical identification of different neuronal cell 
types: arrows – neurons; arrow heads – glial cells 
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Dithioeritritol solution in glycerol and polyvinyl alcohol (4.8.2) was used as a special water 
soluble mounting medium for the microscopy during the cell type identification to enable 
performing the adduct-specific immunostaining of the same probe thereafter. 
 
2.1.3 Immunostaining of specific Pt-DNA adducts 
After the neuronal cell types have been identified, the same probes were stained for Pt-DNA 
adducts according to the ICA protocol, adjusted for different nervous tissues. 
 
2.1.3.1 Fixation, alkaline permeabilisation and proteolytic cleavage 
Several fixation and denaturation techniques have been tested to achieve an optimal 
penetration of the antibodies through the highly myelinated membranes and to provide a 
good access of MABs to the intranuclear epitopes. A combination of Triton X-100 and 
alkaline permeabilisation was found as the best variant for the spinal cord and sciatic nerve. 
Compared to formamide fixation, microwave-denaturation or alkaline treatment alone this 
procedure provided suitable adduct specific nuclear staining with significantly lower 
background signal. 
For the less myelinated DRG tissue sections, however, a single alkaline permeabilisation 
proved to be sufficient to obtain good immunostaining results. 
The proteolysis of cytoplasmic and nuclear proteins with pepsin and proteinase K helped to 
access the antigen determinants and at the same time reduced the undesired non-specific 
antibody binding. Although the intensity of proteolytic cleavage, if applied to a nervous tissue 
section, has to be rather strong, the morphological integrity of cell nuclei should largely be 
preserved, as it is absolutely required for the single cell based adduct quantification. 
Therefore, the optimal enzyme concentrations and digestion conditions were tested and 
adjusted individually for each tissue type (4.8.3). 
 
2.1.3.2 Sandwich immunostaining and DNA counterstaining 
Cisplatin-induced bivalent Pt-DNA adducts were marked with anti-(Pt-GG) MABs and 
secondary labeled with fluorochrome. 
The sensitivity of the adduct-specific immunostaining was significantly improved by applying 
a cascade of several fluorochrome-labeled secondary antibodies for the detection of Pt-DNA 
– anti-(Pt-DNA) immune complexes (Figures 5, 6). Such “sandwich” staining technique 
increases the rate of the fluorescence emission and therefore allows the precise visualization 
and quantification even of relatively low amounts of cisplatin-induced DNA lesions. To 
minimize the background signal, the incubation times of the secondary antibodies were 
reduced, 0.05% Tween 20 solution was applied for additional wash after each step and the 
duration of washes was increased. 
DNA counterstaining with DAPI was used to identify the position of cell nuclei and to perform 
the calculation of relative adduct levels corrected for actual nuclear DNA content of each cell.  
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2.1.3.3 Quantification of relative adduct levels in well defined neuronal cells by 
digital cytometry 
Detection and quantitative analysis of Pt-DNA-adducts were performed by means of the 
fluorescence-microscope coupled digital image analysis system “ACAS”. The cell nuclei were 
localized by DAPI-DNA fluorescence and different cell types were marked manually using the 
digital images obtained at the cell type identification step (figure 5). Adduct levels in nuclear 
DNA of individual cells were calculated by normalizing antibody-derived fluorescence signals 
to the corresponding DNA content of the same cell (in order to correct for the possible DNA 
loss) and expressed as relative units (RU). These data were assigned to specific cell types 
as determined by immuno-histochemistry (2.1.2) Thus, finally, the relative adduct levels 
corrected for nuclear DNA content were used as quantitative parameters (figure 6). The 
mean adduct amounts of at least 200 cells per each cell type were used as values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 5 Detection of Pt-DNA adducts in well defined cell types of the 
murine nervous system at the single cell level: arrows – DRG 
neurons; arrow heads – satellite cells (DRG frozen tissue section, 
24h after single cisplatin treatment) 
Results & comments 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Immuno-Cytological Assay (ICA) for the quantification of 
cisplatin-induced DNA adducts at the single cell level (overview) 
 
Results & comments 16
  
2.2 Formation and repair of specific Pt-DNA lesions in the nervous 
tissue of wild type and DNA repair deficient mice 
 
2.2.1 Study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 Cell type-specific accumulation and repair of Pt-DNA adducts in nervous 
tissue of WT mice 
C57Bl/6 mice were used as wild type (WT), DNA repair proficient animals to establish the 
murine model of acute cisplatin-induced neurotoxicity. Cisplatin was administered as a single 
i.p. injection in the dosages of 2 or 10 mg/kg. The low dose was used as an equivalent to the 
clinical therapeutic dose, the higher dose represented 70 % of the mouse LD50 (Connors et 
al., 1972) and corresponded to the neurotoxic dose in humans (van der Hoop et al, 1990). 
The animals were sacrificed according to the schedules described above (2.2.1). Cell type 
specific accumulation and repair of cisplatin-induced DNA lesions in the central and 
peripheral nervous system were analyzed in the ICA. Animals both under the low or high 
dose treatment showed no signs of vital functions limitation throughout the experiments.  
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After single dose administration of cisplatin (2 mg/kg) Pt-DNA lesions were detectable in all 
cell types investigated. Accumulation of adducts in DRG neurons and satellite cells (outside 
the blood-brain barrier [BBB]) was significantly higher than in the same cell types of the 
spinal cord. Further, the extent of adduct burden was higher in DRG satellite (0.49 ± 0.019 
RU) or spinal cord glial cells (0.28 ± 0.009 RU) than in the neurons of the same anatomical 
structures (0.34 ± 0.013 RU for DRG neurons, 0.23 ± 0.009 RU for spinal cord neurons, p < 
0.01; figure 7). 
Interestingly, the lowest adduct levels were observed in the Schwann cells of the sciatic 
nerve, being about 3.7 times lower than in satellite cells (0.13 ± 0.005 RU versus 0.49 ± 
0.019 RU, p < 0.01) and even lower than in the glial cells of the spinal cord (figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
:, 
 
 
 
 
 
 
 
 
 
Figure 7 Pt-DNA adduct accumulation in different cell types of the murine 
nervous system (WT mouse, 24h after cisplatin treatment 2 mg/kg) 
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Adduct accumulation was dose dependent: 2.08 ± 0.092 RU and 0.66 ± 0.027 RU in DRG 
satellite cells and DRG neurons following single administration of 10mg/kg cisplatin; 0.49 ± 
0.019 RU and 0.34 ± 0.013 RU in DRG satellite cells and DRG neurons following single 
administration of 2 mg/kg cisplatin, p < 0.01 (figure 8). The major accumulation profiles 
remained unchanged under the high-dose schedule: the maximal adduct levels were 
observed in the DRG cells; satellite and spinal cord glial cells contained more DNA lesions 
than corresponding neurons. However, the toxic dose treatment led, probably due to the 
better blood-brain barrier penetration, to an increased adduct formation within the CNS cells, 
so that the adduct levels in spinal cord glial cells even exceeded those of the DRG neurons 
(figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Pt-DNA adduct accumulation in the central and peripheral 
nervous system under the low dose (2mg/kg) and high dose 
(10mg/kg) cisplatin administration (WT mouse, 24h after single 
treatment) 
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Figure 9 Pt-DNA adduct formation - repair kinetic in different neuronal 
cell types of NER proficient C57Bl/6 mice 
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The maximum adduct levels were reached in all investigated cell types 24 hours after 
treatment. Possible reasons for such relatively slow increase in Pt-DNA adduct amount could 
be gradual mobilization of the drug initially bound by plasma proteins, as well as the time, 
necessary for transformation of intermediate monovalent platination products into bivalent 
adducts (Liedert, 2001). The proportions of adduct accumulation between the cell types 
remained unchanged at all observed time points, though the quantitative differences became 
less prominent after repair phase. The adduct elimination profiles representing the efficiency 
of DNA repair were similar in different cell types and under different dose schedules: up to 
70% of lesions were removed in the course of the intensive repair phase, whereas the rest of 
adducts persisted as a plateau-level, which decreased slowly till the latest time point after 
application (5 or 14 days respectively) and represented approx. 30% of the initial burden. 
The duration of intensive repair phase was dose dependent: 24h under the low dose and 48h 
under the high dose cisplatin administration with the exception for satellite cells, where the 
intensive repair phase after high dose treatment was prolonged (due to the high initial adduct 
burden) up to 6 days following the maximal level (figure 9).  
 
 
 
2.2.3 Pt-DNA adduct accumulation - repair kinetic in NER-deficient mice  
To investigate the role of DNA repair in the pathophysiology of cisplatin-induced neurotoxicity 
two NER-deficient mouse strains – XPA- and XPC-knockout – were treated with therapeutic 
dose of cisplatin (2 mg/kg) and sacrificed according to the described schedule (2.2.1). The 
results obtained in the ICA were compared with those of WT mice received the same 
treatment.  
As previously observed in WT mice, adduct levels peaked 24h after treatment. Both NER 
deficient strains showed about two-fold higher Pt-DNA adduct accumulation in all cell types, 
which is already visible as significantly higher immunofluorescence intensity (figure 10). 
The cell type specific accumulation patterns reproduced those of WT mice with high adduct 
accumulation in satellite cells and neurons of the DRG (0.92 ± 0.035 RU in DRG satellite 
cells of XPA-/- mice and 0.92 ± 0.048 RU in those of XPC-/- mice; 0.59 ± 0.034 RU in DRG 
neurons of XPA-/- mice and 0.58 ± 0.039 RU in those of XPC-/- mice) and less accumulation 
in glial cells and neurons of the spinal cord (0.42 ± 0.018 RU and 0.45 ± 0.020 RU in spinal 
cord glial cells of XPA-/- mice and XPC-/- mice; 0.34 ± 0.015 RU and 0.30 ± 0.014 RU in spinal 
cord neurons of XPA-/- mice and XPC-/- mice respectively, p < 0.01; figure 11). 
The Schwann cells of the sciatic nerves showed again the lowest adduct formation rates 
compared to the other glial cell types (0.30 ± 0.018 RU and 0.32 ± 0.022 RU in the Schwann 
cells of XPA-/- mice and XPC-/- mice respectively; figure 11). 
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Figure 10 Detection of Pt-DNA adducts in DRG neurons and satellite 
cells of NER proficient and NER deficient mouse 24h after cisplatin 
treatment, 2mg/kg i.p. 
 
Although the absence of active XPA protein led to a sharp increase in accumulation of 
cisplatin-induced DNA crosslinks, some removal of these lesions still could be observed in all 
the investigated cell types (30% by day 2), indicating that both neuronal and glial cells with 
this defect were nevertheless capable of limited DNA repair (figure 11). 
The nervous tissue cells lacking XPC function were in contrast to WT and XPA-/- cells 
completely unable to eliminate the Pt-DNA crosslinks from the genome and were 
characterized by long term persistence of adducts (figure 11). These findings allow the 
suggestion that the XPC protein but not XPA is essential for the recognition and repair 
processing of bivalent Pt-DNA adducts like Pt-(GG). 
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Figure 11 Platinum-DNA adduct repair kinetics in wild type and DNA 
repair deficient mice 
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2.2.4 Enhanced acute cisplatin neurotoxicity in XPA- and XPC-knockout mice 
The XPA-knockout mice were shown to be extremely sensitive to the toxic effects of cisplatin 
and morphological signs of tubular kidney damage could be observed already 5 days after a 
single administration of 2 mg/kg (Liedert, 2001). In the present experiments an equivalent 
dose of the drug administered as a single i.p. injection was associated with loss of weight 
and with a decreased physical activity in 60% of the XPA deficient animals. Both WT and 
XPC-knockout mice showed under the same conditions neither the signs of constitutional 
toxicity nor morphological signs of renal damage. In order to visualize possible neuronal 
damage all obtained nervous tissues were examined morphologically (HE-staining). 
Prominent morphological changes in the tissue structure of DRG, including shrinkage of the 
cytoplasm and nuclear condensation in the presence of an intact plasma membrane, were 
found in both DNA repair deficient strains already 48 h following cisplatin administration. In 
particular DRG of XPC-/- mice were characterized by massive loss of neuronal cells. In 
contrast to these findings, the morphological integrity of DRG in WT mice was mostly good 
preserved both after low dose and high dose cisplatin treatment (figure 12). Thus, the 
enhanced formation and persistence of cisplatin adducts in the genomic DNA of NER 
deficient nervous cells had drastic morphological consequences leading to cell death. 
  
Figure 12 Extent of morphological damage in DRG tissue of wild type 
and DNA repair deficient mice after single treatment with 2 mg/kg 
cisplatin (HE-staining) 
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2.2.5 Functional evaluation of cisplatin-induced neurotoxicity in mice: 
electrophysiological examination of motor and sensory nerve fibers  
 
In this study I have shown the enhanced formation of cisplatin-induced Pt-DNA adducts in 
DRG sensory neurons compared to the spinal cord cells. Furthermore, accumulation of DNA 
lesions in DRG neurons strongly correlated with the extent of morphological damage, 
increasing significantly in DNA repair deficient nervous cells. However, it still remains open to 
which extent accumulation and persistence of DNA lesions correlate with clinical signs of 
cisplatin-induced polyneuropathy. Therefore, a model was developed, in which both, DNA 
lesion quantification and electrophysiological studies could be assessed in the same animal. 
In a pilot experiment I have investigated the correlation between the accumulation of Pt-DNA 
adducts in neuronal cells of WT and NER-deficient mice and functional impairment under 
chronic cisplatin treatment. WT and XPA-knockout mice were treated with cisplatin, 2 mg/kg, 
once a week or with sterile saline i.p. (controls). 
Electrophysiological tests (M- and H-responses, motor [MNCV] and sensory nerve 
conduction velocity [SNCV] of the sciatic nerve) were performed at cumulative doses of 2, 4 
and 8 mg/kg. The accumulation of cisplatin-induced DNA lesions in different neuronal cell 
types was analyzed in the ICA (4.8). 
In cisplatin treated WT mice electrophysiological parameters did not differ from the control 
WT mice (table 1; figure 13). 
In XPA-/- mice, starting at cumulative dose of cisplatin 4mg/kg, the amplitude of the H-reflex 
was reduced (p<0.01) and the H-reflex-related SNCV began to slow down (not significant). A 
cumulative dose of 8mg/kg caused a highly significant decrease in both sensory parameters 
compared to controls (p<0.01, table 1; figure 13). M-response and MNCV remained 
unaffected in both experimental groups (table 1; figure 13). No electrophysiological 
differences were observed between the NER-proficient and deficient controls (table 1). 
The accumulation of Pt-DNA-adducts was dose dependent and approximately two-fold 
higher in DRG cells than in the same cell types of the spinal cord (table 2). The XPA-/- mice 
showed a significant increase in persisting DNA lesions compared to the WT counter points 
due to an impaired adduct removal in these cells (figure 14). 
A strong association between the enhanced accumulation / persistence of Pt-DNA adducts in 
DRG cells and an early functional impairment of the sensory nerve fibers indicates that the 
amount of persisting DNA lesions is indeed very likely to determine the development of 
cisplatin-induced polyneuropathy. 
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Table 1 Electrophysiological parameters in WT and XPA-/- mice after different 
cumulative doses of cisplatin (chronic treatment, 2mg/kg per week) versus untreated 
littermates 
 Group Untreated 2mg/kg 4mg/kg 8mg/kg 
  Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM 
MNCV m/s WT 64.9 ± 5.5 61.5 ± 3.5 60 ± 2.5 57.2 ± 4.16 
 P vs. control  NS NS NS 
 XPA-/- 66 ± 1.6 57 ± 2.6 57.4 ± 3.4 60 ± 10 
 P vs. control  NS NS NS 
M-response, 
mV WT 5.3 ± 0.5 5.4 ± 0.2 5.2 ± 0.3 5.6 ± 0.4 
 P vs. control  NS NS NS 
 XPA-/- 5.5 ± 0.39 5.9 ± 2.6 5.6 ± 0.4 4.6 ± 0.9 
 P vs. control  NS NS NS 
SNCV m/s WT 43.5 ± 3.5 45.9 ± 1.2 48.3 ± 1.5 42 ± 0.7 
 P vs. control  NS NS NS 
 XPA-/- 47.5 ± 3 47 ± 2.7 36.8 ± 3.1 32.25 ± 1 
 P vs. control  NS NS < 0,01 
H-reflex, mV WT 1.51 ± 0.2 1.7 ± 0.1 1.95 ± 0.3 1.64 ± 0.3 
 P vs. control  NS NS NS 
 
XPA-/- 
P vs. control 
1.83 ± 0.2 
 
1.7 ± 0.75 
NS 
0.89 ± 0.1 
< 0.01 
0.8 ± 0.1 
< 0.01 
NS – not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Electrophysiological examination of peripheral nerves as a 
clinical tool to demonstrate cisplatin-induced neuronal damage 
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Figure 14 Accumulation of Pt-DNA lesions in DRG cells of WT and XPA-/- 
mice under chronic cisplatin treatment (2 mg/kg i.p. once a week) 
 
Table 2 Accumulation of Pt-DNA adducts in the central and peripheral nervous 
system of WT and XPA-/- mice after different cumulative doses of cisplatin (chronic 
treatment, 2mg/kg once a week) 
 Group 2mg/kg 4mg/kg 8mg/kg 
  Mean ± SEM Mean ± SEM Mean ± SEM 
DRG WT 0.40 ± 0.02 0.56 ± 0.02 0.77 ± 0.03 
satellite P vs. control < 0.05 < 0.01 < 0.01 
cells XPA 0.49 ± 0.02 0.80 ± 0.04 1.12 ± 0.07 
 P vs. control < 0.01 < 0.01 < 0.01 
DRG WT 0.22 ± 0.01 0.29 ± 0.02 0.47 ± 0.02 
neurons P vs. control < 0.05 < 0.01 <0.01 
 XPA 0.34 ± 0.01 0.48 ± 0.03 0.75 ± 0.04 
 P vs. control < 0.01 < 0.01 < 0.01 
spinal 
cord WT 0.19 ± 0.01 0.24 ± 0.02 0.30 ± 0.02 
glial P vs. control < 0.05 < 0.01 < 0.01 
cells XPA 0.26 ± 0.01 0.32 ± 0.01 0.44 ± 0.04 
 P vs. control < 0.01 < 0.01 < 0.01 
spinal 
cord WT 0.12 ± 0.01 0.15 ± 0.01 0.22 ± 0.01 
neurons P vs. control < 0.05 < 0.01 < 0.01 
 XPA 0.21 ± 0.02 0.25 ± 0.01 0.31 ± 0.02 
 P vs. control < 0.01 < 0.01 < 0.01 
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3 DISCUSSION 
3.1 Drug-induced peripheral sensory neuropathy is a severe and 
dose-limiting side effect of platinum based chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Cisplatin-induced neuropathy: clinical features  
 
Cisplatin is one of the first line treatments for metastatic testicular and ovarian cancer. It is 
also used to treat bladder and small-cell lung carcinoma. Twenty percent of patients cannot 
be treated optimally because of peripheral sensory neuropathy – the major dose-limiting 
toxicity of cisplatin (1.3). Cisplatin-induced neurotoxicity is very often the reason for stopping 
the anti-tumor therapy or changing the dose regimen. Neurotoxicity depends on the 
cumulative dose and generally occurs in patients receiving more than 300 mg/m2 (Grunberg 
et al., 1989; Walsh et al., 1982). Clinically it is characterized by a predominantly sensory 
neuropathy with diminished vibration perception, loss of tendon reflexes and discomforting 
paraesthesias starting in the lower extremities (Thompson et al., 1984; figure 15). In an 
advanced stage of the neuropathy the patient is ataxic with a pronounced gait disturbance 
due to impaired proprioception. Electroneurography detects a pure sensory axonal and 
secondary demyelinating neuropathy characterized by a reduction of sensory nerve action 
potential amplitude and slowing of sensory nerve conduction velocity (Ashraf et. al., 1990; 
LoMonaco et. al., 1992). 
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Symptoms of neuropathy may start even after cessation of therapy and can persist over the 
following months or years (Grunberg et al., 1989; Strumberg et al., 2002). 
In most instances, cisplatin-induced neuropathy is only partly reversible and in up to 50% of 
cases damage is completely irreversible (Alberts & Noel, 1995; Strumberg, 2002). Therefore, 
it represents an important and persistent limitation of quality of life even when the tumor has 
been successfully treated by the drug. Other platinum compounds in active or experimental 
clinical use, including carboplatin and oxaliplatin, are also associated with sensory 
neurotoxicity to various degrees (Lévi et al., 1997; Machover et al., 1996; Siddiqui et al., 
1997). 
However, the underlying molecular mechanism of cisplatin-induced neurotoxicity remained 
obscure up to now. A rational driven approach to reduce neurotoxic side effects of cisplatin 
and probably of other DNA-reactive drugs is still to be developed. 
 
3.2 Extent of DNA platination, activity of Nucleotide Excision 
Repair and tolerance to persisting Pt-DNA lesions determine 
the cell-type specific sensitivity to cisplatin 
The chemotherapeutic mechanism of cisplatin is believed to involve intrastrand adducts 
formed during cisplatin-DNA interaction in cancer cells (Rosenberg, 1985). Cisplatin-induced 
bivalent Pt-DNA intrastrand adducts inhibit replication and transcription and can lead to the 
programmed cell death (apoptosis) of the target cells (1.4; Fichtinger-Schepman et al., 
1995). 
The degree of cisplatin-induced DNA damage as well as the resultant pathophysiological 
events are known to be cell type specific and interindividually variable. Different 
pharmacokinetic factors, such as kidney clearance, blood-brain barrier, drug import and 
export through the cellular membrane as well as cytoplasmatic detoxification, influence 
adduct formation (1.4.2). The adduct elimination depends on the activity of the nucleotide 
excision repair (NER) – a multistep DNA repair pathway, which includes the activity of the 
Xeroderma pigmentosum proteins XPA – XPG (1.4.3; El-Mahdy et al., 2000; Sancar, 1996; 
Smith et al., 2000; Wani et al., 1999). The capacity of this repair mechanism is rather 
inhomogeneous in different cell types (Kelland, 1994; Masuda et al., 1988). Finally, the 
individual degree of tolerance to persisting Pt-DNA lesions determines the cell survival or 
apoptosis (1.4.4). It has been demonstrated in an animal study that DNA adducts are formed 
in DRG neurons when exposed to cisplatin (Meijer et al., 1999). Further on, cisplatin was 
shown to induce apoptosis in DRG neurons in vitro and in vivo (Gill & Windebank, 1998) as 
well as in DRG satellite cells in vivo (Sugimoto et al., 2000). However, so far there was no in 
vivo evidence that the high sensitivity of DRG neurons and satellite cells to cisplatin might be 
due to the enhanced accumulation and / or persistence of Pt-DNA adducts in these cells. 
Therefore the aim of the present study was to investigate accumulation and repair of specific 
DNA adducts in different cell types of nervous tissue as critical parameters for the cisplatin-
induced neurotoxicity. 
 
Discussion 29
  
3.3 The Immuno-Cytological Assay (ICA) is a suitable tool for the 
single cell quantification of specific Pt-DNA adducts in murine 
nervous tissues 
Accumulation and repair of Pt-DNA adducts are the unambiguous determinants of cisplatin 
cytotoxicity and their prognostic significance definitely outmatches the value of other 
measurable parameters such as plasma platinum concentration, expression of certain pro- or 
antiapoptotic factors or nucleolar size (McKeage et al., 2001; Schellens et al., 1996; van de 
Vaart et al., 2000).  
Until now, limited tools to quantify and monitor structural changes in DNA following the 
administration of DNA-reactive drugs inhibited efforts to gain further insights into the 
interdependence of molecular and morphological changes in cells of the central and 
peripheral nervous system. The development of antisera against platinated DNA opened the 
way for the detection of low-levels of Pt-DNA adducts in vivo. Immunocyto- and 
histochemical application of suitable antibodies allows their morphological localization in both 
tumor and normal tissues. However, the previous attempts to localize and quantify cisplatin-
induced Pt-DNA lesions in DRG tissue, using immunohistochemical techniques, resulted in 
controversial findings: according to Terheggen et al. (1989) the level of Pt-DNA binding in 
DRG satellite cells equaled that in liver cells, but DNA platination could not be shown in DRG 
neurons, whereas Meijer et al. (1999) could observe Pt-DNA adduct formation in DRG 
neurons in 43% of cisplatin treated rats, but only occasionally in DRG satellite cells. This 
discrepancy clearly demonstrates that much more precise immunostaining techniques are 
required to realize molecular dosimetry of these lesions. 
The quantitative in vivo analysis of cisplatin-induced DNA lesions in different cell types of 
central and peripheral nervous system has been successfully realized in the present study at 
the single cell basis. This goal has been achieved using the combination of a newly 
developed monoclonal antibody against cisplatin-induced DNA adducts (anti-Pt-(G-G) MAB) 
with digital immune- and DNA-fluorescence microscopy in the immuno-cytological assay. It 
allows for the first time the cell type identification and the measurement of nuclear DNA 
platination levels in nervous cells within the same specimen (2.1; figure 6). Further 
advantages of this approach are the high specifics and sensitivity of adduct detection due to 
the application of anti-Pt-(GG) MABs and secondary sandwich immunostaining. This proved 
to be especially important for the quantitative adduct measurement in a broad range of 
nervous tissues, characterized by relatively low amounts of Pt-DNA adducts. 
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3.4 Quantification and monitoring of Pt-DNA adducts in different 
neuronal and glial cell types 
Accumulation of specific Pt-DNA adducts was observed in all investigated cell types of the 
central and peripheral nervous system following the single i.p. administration of cisplatin, 
regardless of the dose intensity (2 or 10 mg/kg) and the DNA repair proficiency status. 
The quantification of Pt-DNA adducts revealed different accumulation pattern in the 
investigated cell types.  
First, DNA damage was more pronounced in DRG cells (outside the blood-brain barrier) than 
in the same cell types of the spinal cord: under therapeutic-dose treatment DRG neurons 
accumulated about 1,5 times higher adduct amounts than the spinal cord neurons and DRG 
satellite cells – 1,75 times higher than the glial cells of the spinal cord (see 2.2.2; figure 7). 
This finding is in good agreement with many previous reports on pharmacokinetics and 
tissue distribution of cisplatin itself or its DNA reaction products (Boven et al., 1985; 
Johnsson et al., 1995; Lange et al., 1973; Litterst et al., 1976 & 1979; Roelofs et al., 1984; 
Stewart at al., 1982). Although adduct levels within the CNS, especially in glial cells, 
increased with escalating cisplatin dose, the DRG cells remained nevertheless most affected. 
Hence, the reason for the predominant peripheral sensory neuron toxicity may be the drug 
access rather than the selective neuronal vulnerability. Cisplatin cannot easily cross the 
blood-brain barrier (BBB) and, therefore, motor neurons and other central nervous system 
cells are not directly exposed to toxic levels of the drug. However, if the protection by the 
BBB is weakened, e.g. in the cases of brain tumors or by high dose mannitol 
coadministration, central neurotoxicity can also be observed (Fountzilas et al., 1991). 
Similarly, high levels of Pt-DNA adducts were reported in autopsy brain samples from 
patients, who received multiple cisplatin treatments amounting to high cumulative doses 
(Poirier et al., 1992).  
Second, there was an obvious cell type specific accumulation of adducts within the nervous 
tissues: glial and satellite cells accumulated more DNA lesions than neurons of the same 
anatomical structures. In particular, DRG satellite cells showed 1.4-fold higher extent of DNA 
platination than the corresponding neurons. The prominent Pt-DNA adduct accumulation in 
dorsal root satellite cells has been described elsewhere (Terheggen et al., 1989). This finding 
is also in agreement with several previous reports, where the satellite cells were shown to 
develop severe ultrastructural changes after cisplatin exposure (Cece et al., 1995; Corsetti et 
al., 2000; Sugimoto et al., 2001). One explanation might be that the dorsal root neurons are 
ensheathed by a capsule of satellite cells, which is usually directly apposed to the neuronal 
cell bodies. Therefore, DRG neurons are completely separated from the surrounding 
environment and can only contact the extracellular space through the narrow clefts between 
the wrappings of satellite cells (Tennyson & Gershon, 1993; Pannese, 1981). Satellite cells, 
on the contrary, are facing extracellular space and are directly exposed to the tissue cisplatin 
concentrations. Similar relationships regarding the mechanical support and the trophic 
function are known for neuronal and glial cells within the CNS as well. 
 
Discussion 31
  
Interestingly, a very low adduct formation has been observed in Schwann cells of the sciatic 
nerve throughout all experiments. 
The Pt-DNA adduct levels in these cells under the therapeutic dose of cisplatin were about 
3.7 times lower than in the DRG satellite cells and even lower than in the spinal cord cells. 
Likewise surprisingly low adduct levels have been previously described in the peripheral 
blood lymphocytes, which are directly exposed to the serum cisplatin concentrations (Liedert, 
2001; Terheggen et al, 1988; van de Vaart et al., 2000), as well as in testis, where the Pt-
DNA adducts were restricted to interstitial cells and absent in germ cells, although testicular 
tumors are known to be extremely sensitive to cisplatin (Johnsson et al., 1995; Terheggen et 
al., 1987). Such phenomena reflect the plurality and complexity of pharmacokinetic factors, 
which determine the adduct formation within the particular cell type. As recently shown, low 
adduct levels in specific cell types can be due to reduced influx, accelerated export or 
augmented metabolic inactivation of cisplatin (Giaccone, 2000; Liedert et al., 2003). A 
relatively low DNA platination in Schwann cells within the peripheral nerve might be due to 
the protecting role of the endo- / perineurium, serving as a “blood-nerve barrier” (Low, 1976; 
Tennyson & Gershon, 1993), as well as to a relatively poor vascularisation, compared to 
DRG, which is supplied by fenestrated capillaries (Gill & Windebank, 1998; Lieberman, 
1976). However, the molecular mechanisms responsible for such different adduct formation 
rates in satellite and Schwann cells remain obscure. 
The organ-specific pharmacokinetics of cisplatin has been described in several previous 
reports (Boven et al., 1985; Fichtinger-Schepman et al., 1989; Johnsson et al., 1995; Litterst 
et al., 1979; Terheggen et al., 1987). The present study has performed for the first time a 
monitoring of DNA platination at the level of individual cells within the CNS, DRG and the 
peripheral nerves. 
The time profiles and the elimination parameters of Pt-DNA-adducts measured in different 
cell types of nervous tissue were similar and correlated with those recorded for kidney and 
liver tissue (Liedert, 2001) with some exceptions. This suggests that the DNA repair system 
responsible for the removal of Pt-intrastrand crosslinks is equally active in the investigated 
cells. Peak adduct levels were reached at 24h after treatment (figure 9). Thus, the formation 
of adducts seems to be rate limiting compared to the tissue distribution of the drug: peak 
tissue platinum concentrations are normally achieved at 15 min after i.p. administration 
(Johnsson et al., 1995; Fichtinger-Schepman et al., 1989). This time-lag could be due to the 
relatively slow transformation of intermediate monovalent platination products into bivalent 
adducts, as detected by ICA, or because of the partial removal of adducts from nuclear DNA 
by NER mechanism already at the intermediate stage (Liedert, 2001). 
The biphasic elimination of DNA lesions included an intensive repair phase, when up to 60% 
of lesions were removed within the next 24h – 6 days, depending on the amount of the initial 
adduct burden, and a delayed terminal elimination phase characterized by slowly decreasing 
plateau of unrepaired adducts. The fast initial decline in adduct levels could reflect to a 
certain extent that cells with high initial adduct burden died off. Interestingly, about 30% of 
the initially formed Pt-DNA adducts are obviously “repair-resistant” and can be detected in 
DRG cells even two weeks after cisplatin administration (figure 9). 
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Hence, both, the neuronal and glial cells seem not be capable to completely remove all Pt-
(GG)-intrastrand crosslinks from the genome, even in the DNA repair proficient WT mice. 
This finding might be important for the clinical situation, when the critical amount of 
unrepaired adducts could pile up during repeated “chronic” exposure to the drug. 
Taken together, the highest adduct levels were found in the dorsal root neurons and in the 
supporting satellite cells, which proved to be more affected. The satellite cell damage and 
especially the disorganization of their sheath, which serves as the only protective barrier for 
the DRG neurons, may facilitate the neuronal damage and therefore largely contribute to the 
development of cisplatin-induced polyneuropathy. 
What is the clinical relevance of these results? The pharmacokinetics of chemotherapeutic 
agents, including cisplatin, are similar in humans and in mice (Kubota et al., 1993). Further 
on, the dosages used in both low-dose and high-dose treatment schedules were chosen in 
order to represent the most frequently used therapeutic dose (50 mg/m2) and the cumulative 
dose (300 mg/m2), at which the first clinical signs of neuropathy occur in most of cisplatin 
treated patients. This suggests that the presented here mouse model may provide a fair 
estimate of the formation and repair of cisplatin-induced DNA lesions in human nervous 
system. 
 
3.5 Deficiency in XPA or XPC activity leads to increased adduct 
accumulation in neuronal cells and enhanced acute cisplatin 
toxicity 
The XP (Xeroderma pigmentosum) – gene family encodes a number of essential 
components of the nucleotide excision repair (NER) pathway, which itself is a part of the 
comprehensive DNA damage response network of mammalian cells. Mutations and 
polymorphisms in XP-genes are associated with UV-hypersensitivity, cancer predisposition 
and premature aging (De Boer, 2002; van Steeg et al., 2000). 
The present study has addressed the question to which extent the NER pathway and its 
components are involved in the repair of Pt-DNA lesions within the nervous system. Mice 
deficient in XPA or XPC gene functions were analyzed for the repair kinetics of Pt-(GG) 
crosslinks in the nuclear DNA of neuronal and glial cells of the DRG, spinal cord and 
peripheral nerve. 
As already observed in wild type animals, the adduct formation peaked 24 hours following 
cisplatin administration and the highest adduct levels were found in DRG cells (2.2.3; figure 
11). However, XP-knockout animals were characterized by two-fold higher peak adduct 
levels compared to WT mice both, in the cells inside and outside the BBB. Interestingly, while 
the XPA-/- mice were still capable of limited Pt-DNA adduct removal, in XPC-/- mice these 
lesions were not repaired at all and persisted at the peak level for more than 5 days. 
Thus, this newly established in vivo model is perfectly suitable to analyze the consequences 
of different adduct formation / persistence due to the different DNA repair capacity in primary 
cells on a homogeneous genetic background.  
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The next question addressed was whether this increase in adduct accumulation is indeed 
followed by clinically relevant morphological and functional changes. A morphological 
examination (HE-staining) revealed prominent structural changes in DRG tissues of both 
knockout strains and massive loss of XPC-/- neurons already after a single cisplatin 
treatment. One thus could find a strong correlation between the enhanced adduct 
accumulation / long term persistence of DNA lesions in DRG neurons and the extent of 
morphological damage following cisplatin exposure (2.2.4; figure 12). 
The results of the pilot electrophysiological experiment proved to be nonetheless 
demonstrative. WT and XPA-knockout mice were administered cisplatin chronically for 
several weeks and the correlation has been investigated between the accumulation of Pt-
DNA-adducts in neuronal cells and functional impairment in peripheral nerves (2.2.5). An 
insufficient NER function in the XPA-/- DRG neurons resulted in a high accumulation of 
unrepaired DNA lesions within these cells. To achieve an adduct level comparable to that in 
XPA-/- mice at a cumulative dose of 4 mg/kg cisplatin, WT mice had to receive a two-fold 
higher cumulative dose. Furthermore, the enhanced persistence of Pt-DNA adducts in DRG 
cells of NER deficient XPA-/- mice was strongly associated with an early functional 
impairment of sensory nerves: both, the amplitude of the H-reflex and the SNCV decreased 
significantly (p< 0.01) after the cumulative dose of 8 mg/kg cisplatin, whereas NER 
competent WT mice, which DRG cells were bearing 35% less platinum-DNA lesions, 
remained electrophysiologically intact under the same cumulative dose.  
Thus it seems plausible that the amount of persisting DNA lesions in DRG neurons might be 
the critical parameter which determines the development of cisplatin-induced 
polyneuropathy. The current study conducted by our group is aimed to prove, whether in WT 
mice at higher cumulative doses of cisplatin the amount of unrepaired DNA lesions in DRG 
cells would correlate with the severity of functional changes, according to the dose-
dependent character of sensory polyneuropathy known for patients under the long-term 
cisplatin treatment. 
 
3.6 Role of XPA and XPC proteins on the repair processing of Pt-
DNA adducts in the target cells of nervous system 
The clearly different character of Pt-DNA adduct repair kinetics observed in the two 
investigated NER deficient strains reflects different function of both XP proteins in the 
recognition and repair of DNA lesions which can be described by the following model (figure 
16).  
Cisplatin interacts with the DNA in two steps: first intermediate monovalent platination 
products are formed and second, if not removed within the next several hours, they are 
transformed into “late” bivalent adducts (GG-crosslinks) which are responsible for the drug 
cytotoxicity. According to our data it is most likely that the augmented formation rate of GG-
crosslinks in XPA- and XPC-deficient cells is due to their inability to remove the platination 
products from DNA already at the intermediate mono-adduct stage.  
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Figure 16 Model for the substrate specificity of XPA and XPC proteins 
towards mono- and bivalent Pt-DNA adducts 
 
To say it in other words, the damage recognition and initiation of the repair process must 
happen in NER-proficient WT cells prior to the relatively slow crosslinking reaction resulting 
in comparatively low Pt-(GG) levels in these cells. This “early” repair seems to be under the 
control of both, XPA and XPC proteins. Once formed the crosslinks are recognized and 
excised by the NER mechanism only in the presence of a functional XPC protein, whereas 
XPA is not completely essential for this process. This observation is in good agreement with 
the results reported by Zhen et al. (1993). In accordance with our data, this study on the 
gene-specific repair demonstrated that the human fibroblasts from XP patients lacking active 
XPA protein still possessed a limited nucleotide excision repair capacity and were able to 
remove approx. 22% of cisplatin-induced DNA crosslinks. 
Thus, in our mouse model the impairment of DNA lesion recognition appears to be the most 
deleterious mechanism to initiate the cascade of neuronal cell damage and cell death under 
cisplatin treatment. With regard to the clinical situation it might become a critical pre-
dispositional factor for the onset and / or severity of cisplatin-induced polyneuropathy since a 
broad interindividual variability in DNA repair capacity was observed in humans (Buschfort et 
al., 1997; Buschfort-Papewalis et al., 2002). 
 
Cisplatin
XPC
DNA
Pt Pt
XPC
XPA
NER
Discussion 35
  
3.7 New insight into the pathophysiology of cisplatin-induced 
polyneuropathy 
 
Predominant DNA-damage in DRG neurons and satellite cells may reflect a crucial 
mechanism of sensory polyneuropathy following cisplatin exposure. 
First of all, this finding is in good agreement with previous animal investigations and autopsy 
studies on cisplatin-treated patients. Platinum levels in post mortem tissues are greatest in 
the dorsal root ganglia, although it does accumulate in peripheral nerves, ventral roots, and 
dorsal roots. Levels in the central nervous system are dramatically lower, indicative of 
protection by the blood-brain barrier (Gregg et al., 1992; Poirier et al., 1992 & 1993; Roelofs 
et al., 1984; Stewart at al., 1982; Terheggen et al., 1989; Thompson et al., 1984;). 
Potential anatomic sites of the toxic effect include the DRG neuron cell body, the DRG axon, 
and supporting cells within ganglia and peripheral nerves. While axonal degeneration has 
been observed in post mortem studies, this appears to be a late-stage event secondary to 
changes in the cell body (Roelofs et al., 1984). Additionally, no evidence was found of 
primary demyelination (Thompson et al., 1984). This fact excludes Schwann cells at least 
from the primary targets of cisplatin neurotoxicity and my own observation of low Pt-DNA 
adduct levels in Schwann cells supports this idea. 
The impairment of fast axonal transport due to the microtubuli cross-linking caused by 
platinum-protein interaction was discussed as a potential mechanism contributing to the 
cisplatin-induced neurotoxicity (Boekelheide et al., 1992; Gao et al., 1995). However, no 
changes in microtubuli morphology have been observed under cisplatin exposure (Russell et 
al., 1995). The data on whether cisplatin affects the function of ion channels are scant.  
Cisplatin does not inhibit Na-K ATPase activity in renal tissue in vivo (Uozumi & Litterst, 
1985) and shows no significant influence on excitability parameters of isolated peripheral 
nerves (Grosskreutz et al., 2000; Quasthoff & Hartung, 2002).  
Furthermore, fast axonal transport shows uniformity of velocities across species in motor and 
sensory nerves, in myelinated fibers of varying sizes (Ochs, 1972) and in unmyelinated fibers 
(Ochs & Jersild, 1974). Since cisplatin selectively affects the function of sensory nerve fibers 
(predominantly large myelinated), the primary impairment of fast axonal transport seems 
unlikely to be the underlying mechanism of cisplatin-induced neurotoxicity. 
The data of my experiments now provide evidence, that Pt-DNA crosslinks are indeed being 
formed in the nervous cells under in vivo cisplatin exposure and that the predominant DNA 
damage occurs in the DRG neurons and satellite cells (2.2).  
DNA damage is an initiator of programmed cell death and this is one of the mechanisms by 
which DNA-reactive drugs exert their antitumor potential. Cisplatin has been shown to induce 
apoptosis in DRG neurons in vitro and in vivo (Fischer et al., 2001; Gill & Windebank, 1998) 
as well as in the trigeminal ganglion satellite and Schwann cells in vivo (Sugimoto et al., 
2000). Hence, it seems quite plausible, that the molecular basis for both the cytotoxic action 
and the neurotoxic action of cisplatin is identical.  
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Furthermore, the enhanced accumulation / persistence of Pt-DNA adducts in DRG cells was 
strongly associated with morphological signs of neurotoxicity as well as with an early 
functional impairment of peripheral nerves as shown in the present in vivo study using 
neurophysiological and histological techniques. 
Thus, one can conclude that the amount of persisting DNA lesions might determine the 
development of cisplatin-induced polyneuropathy. 
 
 
3.8 Mechanisms of cell death following cisplatin administration 
The extent of morphological changes after cisplatin, including shrinkage of the cytoplasm, 
nuclear condensation and massive loss of neuronal cells, increased with both enhanced 
formation and persistence of DNA lesions, as observed in DRGs of XPA-/- and XPC-/- mice 
(2.2.4; figure 12). The precise mechanisms of cell death following cisplatin exposure, 
however, are still under debate. As DRG cells usually don’t proliferate the interference of Pt-
DNA adducts with replication processes and the typical cell cycle arrest in G2 after cisplatin 
are clearly not the triggering events of apoptosis in this tissue. Hence, the block of 
transcription is more likely to play the crucial role. This view is supported by the 
hypersensitivity to cisplatin of mice lacking a functional XPA as this protein is involved in 
both, global genomic and transcription coupled repair mechanisms (Furuta et al., 2002). 
Moreover, McDonald & Windebank (2002) have recently shown in an elegant mouse DRG 
explantation model, that cisplatin-induced cell death of neurons is associated with the 
activation of the mitochondrial stress pathway via translocation of the proapoptotic Bcl2-
associated X protein (BAX) to the mitochondrial membrane followed by cytochrome c 
release. This observation together with the finding that the triggering of this cascade is 
independent from functional fas or caspase-8 activity indicates that the mitochondrial 
pathway is the major signaling pathway to apoptosis in cisplatin-exposed neurons. 
Interestingly, bax translocation to mitochondria in this model and the onset of cell death could 
be reduced significantly by co-application of high dosed submaxillary gland nerve growth 
factor (NGF). Whether NGF interferes with the persistence of specific lesions in DNA (e.g. by 
stimulating related repair mechanisms) or abrogates the signaling to bax translocation 
remains to be tested. 
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3.9  Outlook: from understanding the molecular basis of cisplatin-
induced neurotoxicity to the development and testing of 
neuroprotective agents 
Cisplatin-induced neurotoxicity is first of all a clinical problem. Understanding its 
pathophysiology is in the focus of basic research. Although there are still many questions to 
be answered, this particular study has succeeded to develop a mouse model, which enables 
new insights into molecular mechanisms of cisplatin-induced polyneuropathy. According to 
my experimental data, it is very plausible that cisplatin-induced DNA lesions represent the 
primary molecular basis of neurotoxicity. The amounts of persisting Pt-DNA adducts in the 
neuronal target cells (DRG neurons) together with the activity of DNA repair mechanisms 
determine the extent of morphological damage and neurological deficit following cisplatin 
exposure. The adduct formation is influenced by a number of different pharmacokinetic 
factors and is cell type specific (Johnsson et al., 1995; Liedert, 2001; Mustonen et al., 1989; 
Terheggen et al., 1987; own data). Thus, it seems quite reasonable to consider the platinum-
DNA interaction as a therapeutic target: chemoprotective agents should either selectively 
hamper adduct formation or should prevent adduct-induced cellular damage in nervous cells 
without influencing an antineoplastic efficacy of cisplatin. Potential chemoprotective 
substances could be tested in the present mouse model according to these requirements. 
Nerve growth factor, involved in functional maintenance of mature DRG sensory neurons and 
antagonizing the effects of neurotoxic damage to these cells (Donnerer, 2003; Lindsay, 1992; 
Kirstein & Farinas, 2002; Windebank & McDonald, 2002), has recently been shown to rescue 
DRG cells ex vivo from cisplatin-induced apoptosis (McDonald & Windebank, 2002). Hence, 
this substance could become under consideration as a candidate for such neuroprotective 
drugs. 
Another key factor of cisplatin-induced neurotoxicity – the DNA repair capacity – seems to be 
rather a genotype specific feature of highly differentiated cells, which does not depend on the 
metabolic peculiarities of the drug-cell interaction within some tissue. Although, DNA repair 
can obviously not be positively influenced by pharmacological interventions recently 
available, the further investigation of its genuine mechanisms and especially of its key 
regulatory genes is of great importance. A substantial interindividual heterogenity in the DNA 
repair capacity has been observed in the human population (Buschfort-Papewalis et al., 
2002). A low expression of genes, which functions are crucial for the repair processing of Pt-
DNA adducts, can, therefore, be regarded as a serious risk factor for the development of 
polyneuropathy under cisplatin treatment. 
The method developed in this work allows a precise analysis and monitoring of platinum-
DNA lesions in the structures of the central and peripheral nervous system in vivo. Thus its 
possible field of application includes targeting both critical points of cisplatin-induced 
neurotoxicity: designing new neuroprotective drugs and gaining further insights into the 
mechanism of DNA repair. 
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4 MATERIALS AND METHODS 
  
4.1 Animals 
C57Bl/6 mice were used as wild type mice (WT) throughout all experiments. XPA- and XPC-
knockout mice were used as NER deficient animals.  
XPC-deficient mice (Berg et al., 1998; Cheo et al., 1997) were kindly provided by Dr. L. 
Mullenders (University Leiden, NL) with their knockout status verified.  
XPA-deficient mice (Nakane et al., 1995) were a generous gift from Dr. K. Tanaka (University 
of Osaka, Japan). 
WT and XPA-/- mice were propagated by house breeding in the Institute of Cell Biology, 
University of Essen, Germany. Homozygocity of XPA-/- mice was verified by PCR analysis 
(4.2). 
Mice were housed under the diurnal lighting conditions, adhered to a dark phase between 
18.00 – 6.00, allowed daily food “Zuchthaltungsfutter Maus-Ratte 10 H 10” (Eggersmann) 
and water ad libitum, and additionally oat bran once a week. Every half a year two animals 
from each strain were checked for pathogenic microorganisms. 
All experiments have been approved by the state animal welfare board. 
 
 
4.2 Genotype verification of XPA-knockout mice 
To verify the XPA-knockout status of mice a 0,4 – 1,2 cm long piece of tail tip was taken from 
each 4 weeks-aged animal under the local anesthesia. The DNA was isolated with “Qiagen 
DNeasy Kit” (4.2.1), quantified with “SYBR Green I” test (4.2.2) and assessed in PCR (4.2.3). 
 
4.2.1 DNA isolation 
The high-molecular DNA isolation from the mouse tail tissue was performed with “DNeasy 
Kit” (Qiagen) according to the instruction of the manufacturer. 
The purity of the prepared nucleic acids has been tested photometrically at 260 nm and 280 
nm (Spectrophotometer: model 150-20, Hitachi) according to Sambrook et al., 1989. The 
E260/E280 ratio of 1.8 – 2.0 was judged as a neat DNA preparation. The DNA integrity was 
verified with agarose (0.9%) gel electrophoresis (4.2.4). 
 
4.2.2 DNA quantification 
The DNA concentration was quantified with the “SYBR Green I” test (Molecular Probes).  
The required standards with concentration range of 0.1 – 1 µg/ml were prepared in TE buffer 
from high-molecular weight DNA (Roche) and adjusted UV-photometrically 
(Spectrophotometer model 150-20, Hitachi) at 260 nm (50 µg double strand DNA / ml 
corresponds to 1 A 260 ). 
Each well of 96-well-plate (Maxisorp, Nunc) was filled with either 50 µl of the standard DNA 
or 50 µl of the DNA probe to be analyzed.  
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Each standard dilution and each DNA sample were applied twice. 50 µl of the DNA reactive 
fluorescent dye “SYBR Green I” diluted 1:10.000 in TE were added into each well. The test 
plate was then incubated protected from light at 25°C for 15 min. The measurement was 
performed with the excitation at 485 nm and the emission of DNA-fluorescence detected at 
530 nm in a fluorescence plate reader (FL 500, PC-program FL 500 1.D.1, Bio-Tek 
Instruments). The detection limit was determined as 0.001 µg/ml (50 pg DNA/well). 
 
4.2.3 PCR technique 
The PCR was performed according to the modified protocol of Nakane et al., 1995, with the 
final mixture volume of 50 µl. 
The following primers were applied: 
 
Primer A (Upper primer: wild type)   
5´ GTG GGT GCT GGG CTG TCT AA 3´  
Mr: 6.300; 5.30 nmol/A260 
 
Primer B (Lower primer: wild type / knockout)   
5´ATG GCG TGG GTT CTT CTT C 3´  
Mr: 6.210; 5.44 nmol/A260 
 
Primer C (Upper primer: knockout):    
5´ ATG GCC GCT TTT CTG GAT TC 3´  
Mr: 6.170; 5.62 nmol/A260 
 
The PCR reaction mixture (40 µl) was prepared under contamination control according to the 
following scheme and kept on ice until adding the DNA. 
Component Concentration 
of the original 
solution 
Entry volume 
[µl] 
Concentration in the 
mixture 
H2O -- 34 -- 
Primer A 400 µM 0.03 250 nM 
Primer B 400 µM 0.03 250 nM 
Primer C 400 µM 0.03 250 nM 
d NTP (Amersham Pharmacia)  25 mM 0.4 200 µM 
AccuTherm – Buffer 10 x 5 1 x 
AccuTherm-Polymerase (GeneCraft) 5 U / µl 0.3 0. 03 U / µl 
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10 µl of the isolated DNA (20 µg/ml in H2O) were added to the reaction mixture. The PCR 
was then performed under the following temperature profile (PCR-engine: MJ Research PTC 
200, Biozym): 
 
time temperature cycles 
1 min 94 o C 1 
25 s 94 o C 34 
30 s 55 o C 34 
60 s 72 o C 34 
4 min 72 o C 1 
 
 
The PCR products were analyzed by electrophoresis in 3% agarose gel (4.2.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Genotype determination of hetero- and homozygous XPA-
knockout mice (3% agarose gel) 
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4.2.4 Agarose gel electrophoresis 
To verify the DNA integrity after the isolation from the mouse tail tip (4.2.1) and to analyze 
the products of PCR the following concentrations of agarose gel were used: 
 
agarose 
concentration [%] 
aim of application mg of agarose  
for 50 ml TAE-buffer 
0.9 DNA isolation (4.2.1) 450 
3 PCR products (4.2.3) 1.500 
 
The required amount of “Biozym Agarose” (0.9%) or “Biozym Small DNA Agarose” (3%) was 
solved in 50 ml of TAE-buffer and microwaved at 700 W for 2 min. 4 µl of ethidiumbromide 
were added into the gel before allowing it to solidify. 12.5 µl of each sample were supplied 
with 2.5 µl of 6x loading buffer and applied for electrophoresis which was performed in 
1xTAE at 50 V for 2 hours. The “GeneRuler” 50 bp, 100 bp or 1kb DNA ladders (MBI) were 
used as standards. The results were evaluated with the UV-transilluminator (Bachmann). 
 
4.3 Experimental design 
Mice of experimental groups were treated with cisplatin (Platinex, Bristol Arzneimittel GmbH, 
München); control animals were treated with sterile saline. Injections were performed 
intraperitoneal (i.p.). Mice were weight and checked for signs of drug toxicity at least twice 
per week. Animals showing signs of distress were immediately and painlessly sacrificed. 
To investigate cell type specific Pt-DNA adduct accumulation and repair in different cell types 
of nervous tissue, WT mice were treated with a single cisplatin dose of 2 or 10 mg/kg; XPA-/- 
and XPC-/-animals received a single cisplatin injection of 2 mg/kg. Following cisplatin or 
sterile saline administration 6h, 12h, 1, 2 or 5 days after low dose treatment or 6h, 12h, 1, 3, 
7 or 14 days after high dose treatment, animals were sacrificed by supramaximal anesthesia 
with diethyl ether. 
To investigate the correlation between the accumulation of Pt-DNA-adducts in neuronal cells 
and functional impairment WT and XPA-knockout mice were treated with cisplatin, 2 mg/kg, 
once a week or with sterile saline i.p. (controls). To prevent renal damage, 1ml of sterile 
saline was injected i.p. immediately after each cisplatin treatment. Electrophysiological tests 
(M- and H-responses, motor [MNCV] and sensory nerve conduction velocity [SNCV] of the 
sciatic nerve, 4.9) were performed at cumulative doses of 2, 4 or 8 mg/kg one week after the 
last treatment. Mice were sacrificed immediately after the examination. Frozen tissue 
sections were prepared from DRG and spinal cord. The accumulation of cisplatin-induced 
DNA lesions in different neuronal cell types was analyzed in the ICA (4.8). 
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4.4 Preparation of tissue samples 
The sacrificed animals were immediately and carefully perfused with 20 ml of sterile saline 
via intracardiac catheterization and underwent dissection. To prevent the nervous structures 
from early enzyme-induced postmortal morphological damage, the carcass was kept on ice 
during the organ dissection and the exposed organs were constantly rinsed with PBS 
(0.01M, pH 7.4) precooled to 4°C.  
A midline dorsal longitudinal incision was made over the toracal and lumbar spine till sacrum. 
The lamina was gently exposed between the spinal muscles and laminectomy Th12-S1 was 
performed microscopically (stereomicroscope Stemi SV 6, lens W – Pl 10x / 1, Zeiss). The 
lumbar part of the spinal cord and the lumbar DRG were exposed. Two DRG (L4, L5) at each 
side and a specimen of the spinal cord were dissected. The sciatic nerve was exposed at 
each side by a slanting incision from the sciatic notch to the knee bend and a specimen of 
approximately 1 cm was dissected. 
Freshly dissected tissue samples were immediately submerged into the embedding medium 
(Tissue-Tek O.C.T. Compound, Sakura Finetek Europe B.V., The Netherlands) and deep 
frozen in liquid nitrogen. Frozen tissue blocks were stored in sealed freezing vials at -80°C. 
 
4.5 Frozen tissue sections 
Frozen tissue blocks were placed into the chamber of the cryostat (2800 Frigocut, Reichert-
Jung), allowed to equilibrate to the chamber temperature (-21°C) for about 30 minutes, 
bound with the embedding medium to the specimen block and mounted on the stub. The 
stub temperature was kept at –19°C while cutting. 7 mm thick tissue sections were 
immobilized onto aminosilan-coated microscope slides and dried at 25°C for 24 hours. The 
samples were stored at – 80°C until assessed in the ICA. 
 
4.6 Haematoxylin-eosin (HE) staining of frozen tissue sections 
Frozen tissue sections were warmed up to room temperature and fixed in an acetone bath at 
25°C for 10 min. Subsequently the slides were immersed into the aqueous haematoxylin 
solution (2 g haematoxylin/I, 0.2 g NaIO3/l, 17.6 g KAl(SO4)2/l) for 5 min at 25°C. Following 
that, the slides were rehydrated for 10 min and stained in 1% ethyl alcohol / eosin solution for 
5 min. After a short water bath the slides were dehydrated in 70% ethyl alcohol, in 96% ethyl 
alcohol, in 100% ethyl alcohol and in xylene by immersing in each solution twice and finally 
embedded (Entellan, Merck). Morphological examination of the samples was performed by 
light microscopy (Axiovert 135, lens Plan-Neofluar 40x / 0.75, Zeiss). 
 
4.7 Preparation of the monoclonal antibodies against Pt-DNA 
adducts 
The monoclonal antibodies (MAB) against cisplatin-induced Pt-DNA adducts have been 
kindly provided by Dr. B. Liedert, Institute of Cell Biology, University of Essen. The 
generation and characterization of the MABs are described elsewhere (Liedert, 2001). 
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4.8 The Immuno-Cytological Assay (ICA) optimized for the single 
cell quantification of cisplatin-induced Pt-DNA-adducts in 
different cell types of the nervous system 
4.8.1 Tissue immobilization 
A special pretreatment of microscope slides keeps the tissue sections properly attached to 
the slide surface and prevents them from washing away during the ICA procedure. For this 
purpose the slides were coated with 2% 3-aminopropyl-triethoxysilan (aminosilan) solution in 
acetone at 25°C for 2 min, washed in acetone at 25°C and dried at 42°C for one hour. 
Frozen tissue sections were placed onto the coated slides, dehydrated at 25°C for 24h and 
stored at – 80°C until assessment. 
 
4.8.2 Immuno-histochemical identification of cell types 
In order to perform cell type specific quantification of Pt-DNA adducts in nervous tissue, the 
neurons as well as glial or satellite cells were labeled immunohistochemically.  
The frozen tissue sections of the DRG or spinal cord were fixed in methanol at – 20°C for 
12h and subsequently rehydrated for 10 min in PBS, pH 7.4, at 25°C. To permeabilize the 
tissues and allow a good penetration of antibodies and staining agents the slides were 
treated in a 0.1% Triton X-100 / PBS at 25°C for 10 min, followed by washing in a PBS at 
25°C. The non-specific protein binding was inhibited by incubation with 1% casein / PBS 
solution for 30 min at 25°C, followed by two washes in PBS. In the next step 100ml of Mouse 
IgG1 monoclonal anti-CNPase (marker for oligodendrocytes and satellite cells, 5mg/ml in 1% 
casein / PBS, Sigma) were applied to each slide and the samples were incubated for 90 min 
at 37°C in the humidified chamber. Subsequently the slides were washed in 0.05% Tween 20 
/ PBS for 2 min at 25°C and then in PBS for 5 min. In the following step 100ml of “ALEXA 
FLUOR 488” – Goat anti-Mouse IgG (H+L) (5mg/ml in 1% casein / PBS, Molecular Probes) 
were applied to each slide and the samples were incubated for 1 h at 37°C in the humidified 
chamber. Subsequently the slides were washed in 0.05% Tween 20 / PBS for 2 min at 25°C 
and in PBS for 5 min. This was followed by an incubation with the “NeuroTraceä 530/615 red 
fluorescent Nissl Stain” (marker for neurons, Molecular Probes), 100ml per slide (1:50 dilution 
in PBS) for 20 min at 25°C in the humidified chamber. Subsequently the slides were washed 
with two changes of PBS for 5 min each, followed by a 2h-long wash in PBS at 25°C. The 
DNA-counterstaining was then performed with 1mg/ml DAPI in PBS for 30 min at 25°C. 
Consequently the slides were washed in PBS at 25°C. Finally, the slides were mounted in 
dithioeritritol solution (4,4mg/ml dithioeritritol (Sigma) in 60% of 50mM Tris/HCl, pH 8.2, 30% 
of glycerol, 10% of 10% polyvinyl alcohol) and covered with coverslips.  
The digital images of the sections and the cell type identification were performed by means 
of laser-scan microscopy (Axiovert 100 with the LSM 510 digital measuring and evaluation 
system, Zeiss). The DRG and the spinal cord neurons were determined by red, glial or 
satellite cells – by green fluorescence, the cell nuclei – by DAPI / blue fluorescence. 
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The images were stored electronically. The coverslips were then gently removed and the 
sections were rehydrated and kept in PBS at 25°C for further assessment in the ICA. 
 
4.8.3 Immuno-Cytological Assay 
The tissue sections of the DRG, spinal cord or sciatic nerve were fixed in methanol at – 20°C 
for 12h and subsequently rehydrated for 10 min in PBS, pH 7.4, at 25°C. An RNA-digestion 
was performed with 100 µl of RNAse solution per slide (200 µg/ml RNAse A & 50 U/ml 
RNAse T1 in PBS) for 1 h at 37°C in the humidified chamber followed by one wash in PBS at 
25°C. To provide a better penetration of antibodies in the tissue structures with high myelin 
content the probes of the spinal cord and the sciatic nerve first were treated in 0.1% Triton X-
100 / PBS at 25°C for 10 min, followed by washing in PBS at 25°C. As a next step an 
alkaline permeabilisation of cytoplasmic and nuclear membranes was performed (60% 70 
mM NaOH / 140 mM NaCl, 40% methanol) for 5 min at 0°C in container, followed by wash in 
PBS at 25°C. The DRG sections were undergoing an alkaline permeabilisation as described 
above immediately after the RNA-digesting step without pre-treatment with Triton X-100. In 
the following, a two-step proteolytic cleavage of cytoplasmic and nuclear proteins was 
performed. At first the sections were incubated with pre-warmed pepsin solution, 100 µl per 
slide (DRG: 300 µg/ml in 20mM HCl; the spinal cord: 600 µg/ml in 20mM HCl; the sciatic 
nerve: 1000 µg/ml in 20mM HCl) for 10 min at 37°C in the humidified chamber, followed by a 
wash in PBS at 25°C. In a second step the samples were treated with pre-warmed 
proteinase K solution, 100 µl per slide (100 µg/ml of proteinase K in 20mM Tris/HCl, 2mM 
CaCl2 , pH 7.5) for 10 min at 37°C in the humidified chamber. Consequently the slides were 
washed in 0.2% glycine / PBS for 10 min at 25°C. Non-specific protein binding was inhibited 
by incubation with 1% casein / PBS solution for 30 min at 25°C. Then the samples were 
incubated with anti-(Pt-DNA) MABs, 100 µl per slide (0,1 µg/ml in PBS, 1% casein, 200 µg of 
sonicated calf thymus DNA / ml) for 2 h at 37°C in the humidified chamber. Subsequently the 
slides were washed in 0.05% Tween 20 / PBS for 2 min at 25°C and then in PBS for 5 min. 
Then the incubation with FITC- Goat IgG F(ab´)2  anti-(Rat [IgG + IgM (H+L)]), 100 µl per 
slide, was performed (6.5 µg/ml in PBS, 1% casein, Dianova) for 45 min at 37°C in the 
humidified chamber, followed by washing of the slides in 0.05% Tween 20 / PBS for 2 min at 
25°C and then in PBS for 5 min. To amplify the immunofluorescence signal a “sandwich” 
immunostaining with a cascade of secondary antibodies was performed. First, 100 µl of 
“ALEXA FLUOR 488” – Rabbit IgG anti-(FITC) were applied to each slide (5 µg/ml in PBS, 
1% casein, Molecular Probes) and the probes were incubated for 45min at 37°C in the 
humidified chamber. Subsequently the slides were washed in 0.05% Tween 20 / PBS for 2 
min at 25°C and in PBS for 5 min. This was followed by an incubation of the samples with 
“ALEXA FLUOR 488” – Goat anti-(Rabbit IgG (H+L)), 100 µl per slide (5 µg/ml in PBS, 1% 
casein, Molecular Probes) for 45min at 37°C in the humidified chamber. Subsequently the 
slides were washed in 0.05% Tween 20 / PBS for 2 min at 25°C and in PBS for 5 min. The 
DNA-counterstaining was then performed with 1mg/ml DAPI in PBS for 30 min at 25°C. 
Consequently the slides were washed in PBS at 25°C. 
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Finally, the probes were embedded with a densification compound “VECTASHIELD” 
(Vector). The quantification of immune- and DNA-fluorescence was performed by means of 
microscope-coupled digital image analysis system (fluorescent microscope Axioplan, lens 
Plan-Neofluar 40x / 0.75, Zeiss; mercury lamp HBO 100 W; DAPI-filter: excitation 365 nm, 
emission 397 nm; FITC / ALEXA 488- filter: excitation 450 – 490 nm, emission 515 – 565 nm; 
charge-coupled device camera C4880, Hamamatsu; ACAS 6.0 Cytometry Analysis System, 
Ahrens Electronics). Adduct levels in the nuclear DNA of individual cells were calculated by 
normalizing antibody-derived fluorescence signals to the corresponding DNA content of the 
same cell nucleus and expressed as relative units (RU). Data were assigned to specific cell 
types as determined by histochemistry 
 
 
4.9 Electrophysiological examination of motor and sensory nerve 
fibers 
All electrophysiological examinations were carried out under general anesthesia (Inactin®, 
Sigma, 50 mg/kg body weight, i.p.). To minimize effects of body temperature differences on 
conduction velocity, animals were placed over a warm flat steamer controlled by a hot water 
circulating pump, and the hind paw skin temperature was maintained at 37-38°C. The tibial 
and sciatic nerves were stimulated percutaneously through a pair of monopolar needle 
electrodes placed at the ankle and sciatic notch, respectively. Square-wave electrical pulses 
of 0.7-msec duration were delivered by Pulsemaster™ A 300 stimulator through an A 365 
stimulus isolation unit (World Precision Instruments, USA). The stimuli were applied starting 
from 0.1mA up to 25% above the amperage that gave a maximal response.  
Upon stimulation of the mixed sciatic or tibial nerve, two responses occur. The M-response is 
a direct motor response with short latency due to stimulation of the á-motor fibers. The H-
reflex is an indirect response with long latency due to stimulation of the afferent 
proprioceptive Ia fibers. The Ia fibers monosynaptically excite á-motor neurons in the spinal 
cord (figure 18). At lower stimulation intensities only the thicker afferent fibers are excitated 
and only an H-reflex is elicited. At increasing stimulation intensities both H- and M-responses 
occur, while at repeated supramaximal stimulation the H-reflex is absent due to antidromic 
conduction in the motor axons (De Koning et al., 1989). 
The compound muscle action potentials (CMAPs) elicited by orthodromic conduction (M-
response) and by the monosynaptic reflex arc (H-response), were recorded from the third 
interosseous muscle of the hindfoot with a pair of microneedle recording electrodes. Mice 
were grounded by means of a needle electrode inserted between the stimulation and 
recording points. After amplification (INH 4-channel differential amplifier, Science Products 
GMBH) the evoked action potentials were sampled and analyzed by means of a CED 
micro1401 system with the “Signal for Windows Version 2.05” software (Cambridge 
Electronic Design Limited, UK), running under Windows 98 on an IBM PC.  
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The amplitude of M- and H-responses was measured from baseline to the maximal negative 
peak and expressed in mV. The response latencies (ms) were defined as the interval 
between the stimulus artifact and the beginning of the M- or H-response. The distance 
between the two stimulation points was measured over the skin with the hip and knee in a 
flexed position. Motor (MNCV) and H-reflex-related sensory nerve conduction velocity 
(SNCV) were calculated as follows:  
MNCV [m/s]=distance (sciatic notch-ankle) / latency (M-response sciatic notch – M-response 
ankle);  
SNCV [m/s]=distance (sciatic notch-ankle) / latency (H-response ankle – H-response sciatic 
notch). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Electrophysiological examination of motor and sensory nerve 
fibers: schematic illustration of the test model. The pictures show the 
M- and H-responses recorded from small muscles of the foot by a 
pair of microneedle electrodes after stimulating at the sciatic notch 
(proximal) and ankle (distal), respectively.
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4.10 Data analysis 
In all experiments for quantitative analysis of cisplatin-induced DNA lesions in different cell 
types of central and peripheral nervous system two treated mice and one control were used 
per time point. From each mouse four dorsal root ganglia (lumbar), the lumbar part of the 
spinal cord and both sciatic nerves were dissected. From each DRG 30 sections, from the 
spinal cord 100 sections and from the sciatic nerve 50 sections were prepared. 10 sections 
of each tissue sample were analyzed chosen at random. In total a minimum of 200 cells of 
each cell type per animal were analyzed. The calculation of Pt-DNA adducts levels was 
made using “SigmaPlot 4.0” software (Jandel Scientific). The results are given in relative 
units (mean +/- SE). 
In all electrophysiological experiments ten treated mice and ten age-matched controls were 
used per time point. 
 
4.11 Statistics 
Statistical significance of the relationships between experimental data was assessed by 
means of ANOVA for repetitive measurements and by the multiple t-Test post-hoc analysis 
performed using SPSS 9.1 software (SPSS Inc.). A two-sided P value of < 0.05 was 
regarded as indicating statistical significance. 
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SUMMARY 
Neurotoxicity with polyneuropathy as its predominant clinical sign is the major dose limiting 
side effect of chemotherapy with DNA reactive drugs such as cisplatin. The underlying 
mechanisms, however, are still not clear. Platinum compounds are known to exert their 
antineoplastic activity by forming distinct Pt-DNA adducts. Both the DNA repair rates and the 
extent of tolerance to persisting lesions determine the cell type specific sensitivity to cisplatin. 
In this report, DNA damage and repair are investigated with regard to their contribution to 
cisplatin-induced neurotoxicity in a mouse model. As the nucleotide excision repair (NER) 
pathway is considered to be an important mechanism for the processing of Pt-DNA lesions, 
its role was studied in an experimental setting with NER-deficient mice lacking functional 
XPA or XPC proteins. Employing monoclonal antibodies, structurally defined DNA lesions 
were quantified in various cells of the central and peripheral nervous system in wild type 
(WT) and repair deficient mice at different time points after a single exposure to cisplatin. In 
order to clarify, if accumulation of DNA lesions correlates with functional impairment, adduct 
quantification and electrophysiological studies were assessed in WT and XPA-/- mice under 
chronic cisplatin administration. The accumulation of Pt-DNA-adducts was dose dependent 
and two-fold higher in dorsal root ganglion (DRG) neurons and satellite cells (outside the 
blood-brain barrier) than in the same cell types of the spinal cord. Furthermore satellite and 
glial cells showed a higher adduct burden than corresponding neurons. Pt-DNA lesions 
peaked in all cell types of nervous tissue 24 hours after treatment. In the cells of DNA repair 
proficient WT mice adducts were removed by DNA repair within 7 days to a level, which 
represented 30% of the initial burden. Both NER deficient strains showed increased Pt-DNA 
adduct accumulation due to the insufficient repair of early monovalent adducts, which are 
known to occur as intermediate structures during cisplatin-DNA interaction. As a 
consequence, a massive loss of DRG cells was detected 48h after cisplatin application. 
While in the absence of active XPA protein some reduction of DNA lesions still could be 
observed, the loss of XPC function resulted in a complete lack of repair and in long term 
persistence of high adduct levels. Under chronic treatment, XPA-/- mice showed a significant 
increase in persisting DNA lesions compared to the WT counter points due to an impaired 
adduct removal in these cells. Furthermore, the enhanced persistence of Pt-DNA adducts in 
DRG cells of DNA repair deficient mice was strongly associated with an early functional 
impairment of sensory nerves: both, the amplitude of H-reflex and sensory nerve conduction 
velocity decreased significantly, whereas NER competent WT mice, bearing 35% less 
platinum-DNA lesions in their DRG cells, remained electrophysiologically intact under the 
same cumulative doses. Thus, there was a strong correlation of Pt-DNA adduct levels in 
DRG neurons with the extent of their morphological damage and with electrophysiological 
changes in sensory nerve fibers. The obtained data suggest that accumulation of DNA 
adducts is the crucial factor in the development of cisplatin-induced sensory polyneuropathy. 
Elucidation of these pharmacokinetic and pharmacodynamic processes is the basis for the 
development of neuroprotective substances which should prevent patients from the therapy-
induced neuronal damage without blocking anti-neoplastic effects of cisplatin in malignant 
cells. 
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APPENDICIES 
 
Devices 
 
Centrifuge:   Biofuge B‘‘ (Heraeus Christ) 
 
Cryostat  “2800 Frigocut“ (Reichert-Jung); 
 
Electrical pulse stimulator “Pulsemaster A 300” (World Precision Instruments) 
  Electrical stimulus isolation unit “A 365” (World Precision  
  Instruments) 
 
Electrical signal amplifier “INH 4-channel differential amplifier” (Science Products) 
 
Electrical signal sampling 
system “CED micro1401” (Cambridge Electronic Design) 
  Software “Signal for Windows 2.05” (Cambridge Electronic 
  Design) 
 
Fluorescent microscope  “Axioplan” (Zeiss) 
   Lens “Plan-Neofluar“ 40x / 0.75, (Zeiss)  
   Mercury lamp “HBO 100 W“ (Zeiss) 
   CCD camera “C4880“ (Hamamatsu)  
   “ACAS 6.0“ Cytometry Analysis System (Ahrens Elektronics) 
 
Fluorescence plate reader  “FL 500“ (Bio-Tek Instruments) 
   PC-program “FL 500 1.D.1“ (Bio-Tek Instruments) 
 
Heater “PMC digital dry block heater” (Roth) 
 
Laser-scan microscope  “Axiovert 100“ (Zeiss) 
   Digital measuring & evaluation system “LSM 510“ (Zeiss) 
 
Light microscope  “Axiovert 135” (Zeiss) 
     Lens “Plan-Neofluar” 40x / 0.75 (Zeiss) 
 
Microwave   (Bosch) 
 
PCR-device    “MJ Research PTC 200“ (Biozym)  
 
Power Supply:  “Electrophoresis power supply‘‘ (Renner GmbH) 
 
Spectrophotometer  “Model 150-20“ (Hitachi); 
 
Stereomicroscope  “Stemi SV 6” (Zeiss) 
     Lens “W-Pl” 10x / 1 (Zeiss) 
 
UV-transilluminator   (Bachmann) 
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PC programs 
Control programs see Devices 
Excel 2002 (Microsoft) 
iPhoto Plus 4 (Ulead Systems Inc.) 
PowerPoint 2002 (Microsoft)  
Sigma Plot 4.0 (Jandel Scientific) 
SPSS 9.1 (SPSS Inc.) 
Word 2002 (Microsoft). 
 
Chemicals 
Chemicals were at least “p.a.” grade and obtained from Merck, with the following exceptions: 
Agarose (Biozym)  
Aminopropyl-triethoxysilan (Sigma) 
Block protein “Rad-Free“ (Schleicher & Schuell) 
Cisplatin “Platinex“ (Bristol Arzneimittel GmbH)  
dATP, dCTP, dGTP, dTTP-mixed for PCR (Amersham Pharmacia Biotech) 
Dithioeritritol (Sigma) 
Ethidiumbromide (Serva) 
Calf thymus DNA (Roche) 
“NeuroTraceä 530/615 red fluorescent Nissl Stain” (Molecular Probes) 
Tissue-Tek O.C.T. Compound (Sakura Finetek Europe B.V.) 
Triton X-100 (Sigma) 
Tween 20 (Sigma) 
Embedding medium “Vectashield“ (Vector) 
 
Buffers and solutions 
The buffers and solution used in the experiments were composed as described in Materials 
and Methods (4.1), except following compounds: 
PBS    10mM Na2HPO4 
    0.13M NaCl 
    pH 7.4 
 
TAE-buffer   0.04M Tris-acetate 
    0.001M EDTA; pH 7.5 
 
TE-buffer   10mM Tris 
    1mM EDTA; pH 7.5 
 
Kits 
DNA-isolation   “DNeasy Kit“ (Qiagen) 
DNA-quantification  “SYBR Green I“ (Molecular Probes) 
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Molecular weight standards 
 
DNA size-standards    „GeneRuler 50 bp, 100 bp and 1 kb DNA Ladder“ (MBI)  
 
Enzymes 
AccuTherm-Polymerase (GeneCraft) 
Pepsin (Roche) 
Proteinase K (Merck) 
RNAse A (Roche) 
RNAse T1 (Roche) 
 
Antibodies 
“ALEXA FLUOR 488” – Goat anti-Mouse IgG (H+L) (Molecular Probes) 
“ALEXA FLUOR 488” – Goat anti-(Rabbit IgG (H+L)) (Molecular Probes) 
“ALEXA FLUOR 488” – Rabbit IgG anti-(FITC) (Molecular Probes) 
FITC- Goat IgG F(ab´)2  anti-(Rat [IgG + IgM (H+L)]) (Dianova) 
Mouse anti-CNPase IgG1 MAB (Sigma) 
 
PCR primers 
MWG Biotech: 
Primer A (Upper primer: wild type)   
5´ GTG GGT GCT GGG CTG TCT AA 3´  
Primer B (Lower primer: wild type / knockout)   
5´ATG GCG TGG GTT CTT CTT C 3´  
Primer C (Upper primer: knockout):    
5´ ATG GCC GCT TTT CTG GAT TC 3´  
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Abbreviations 
 
A adenine 
AAS atom absorption spectrometry 
ABC ATP binding cassette 
ATP adenosine triphosphate 
BAX Bcl2-associated X protein 
bp base pair 
BBB blood-brain barrier 
C cytosine 
CMAP compound muscle action potential 
cMOAT canalicular multispecific organic anion 
transporter 
CNS central nervous system 
DNA desoxyribosenucleic acid 
dNTP desoxyribosenucleotide triphosphate 
DRG dorsal root ganglion 
EDTA ethylendiaminetetraacetate 
ELISA enzyme-linked immuno-sorbent assay 
EMG electromyography 
G guanine 
HE Haematoxylin-eosin 
ICA Immuno-Cytological Assay 
ICP-MS inductively coupled plasma mass 
spectroscopy 
i.p. intraperitoneal 
kb kilobase pair 
k.o. knockout 
LD50 50% of the lethal dose 
MAB monoclonal antibody 
MNCV motor nerve conduction velocity 
MRP multidrug resistance protein 
NER nucleotide excision repair 
NGF nerve growth factor 
NMR nuclear magnetic resonance 
PBS phosphate-buffered saline  
PCR  polymerase chain reaction  
PNP peripheral polyneuropathy 
Pt platinum 
RNA ribonucleic acid 
RU relative unit 
SC spinal cord 
SN sciatic nerve 
SNCV sensory nerve conduction velocity 
TAE Tris-acetate-EDTA 
T thymine 
TE Tris-EDTA 
Tris Tris-(hydroxymethyl)-aminomethane 
U relative enzyme unit 
UV ultraviolet 
WT wild type 
XP Xeroderma pigmentosum 
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